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ABSTRACT
The 8-aminoquinoline (8AQ) antimalarial drug primaquine (PQ) is the only drug for
prevention of malaria relapse. Moreover, PQ also has gametocytocidal activity against
Plasmodium falciparum. However, clinical use of PQ has been limited due to its hemolytic
toxicity, especially in glucose-6-phosphate dehydrogenase deficient (G6PDd) individuals.
Phenolic and quinone metabolites generated via cytochrome P 450-dependent pathways appear to
be responsible for hemolytic effects of PQ. However, the mechanism for the hemolytic toxicity of
PQ is still poorly understood.
To explore the mechanism, targets, and pathways for toxicity of PQ, normal and G6PDd
human erythrocytes were treated with the potential hemotoxic metabolites of PQ namely, 5hydroxy-primaquine (5-HPQ), 5,6-orthoquinone primaquine (5,6-OQPQ) and 6-methoxy-8hydroxylaminoquinoline (MHQ). The early and late biomarkers of hemotoxicity were investigated
to explore the mechanism of PQ toxicity. 5-HPQ, 5,6-OQPQ, and MHQ caused marked increase
in methemoglobin formation and generated robust oxidative stress in both normal and G6PDd
human erythrocytes. However, these metabolites depleted reduce glutathione (GSH) levels
selectively in G6PDd human erythrocytes. Treatment with 5,6-OQPQ also induced eryptosis in
G6PDd erythrocytes, as determined by phosphatidylserine exposure (Annexin V binding).
This study was further extended to investigate the role of NRH-quinone oxidoreductase 2
(NQO2) in PQ-induced hemolytic toxicity. NQO2, has a potential function in metabolic
detoxification or activation of quinones and quinone-based drugs. Co-treatment of erythrocytes
ii

with NQO2 inhibitors potentiated the hemotoxic response of PQ metabolites. The computational
docking studies suggested stronger interactions of PQ metabolites with NQO2 compared to
melatonin (the NQO2 inhibitor) and menadione (the NQO2 substrate). Together these results
suggest that NQO2 might have a protective role against PQ-induced hemolytic toxicity.
The PQ metabolite, 5,6-OQPQ was further evaluated for the effects on the non-targeted
global metabolomic profile of normal and G6PDd human erythrocytes. The GSH-methionineglutamate pathway metabolites were greatly affected by G6PD deficiency. Treatment with 5,6OQPQ also significantly modified GSH-methionine-glutamic acid pathway in erythrocytes.
Treatment also increased the levels of antioxidant and hemolysis related markers in erythrocytes.
These studies provide a better insight into the pathophysiology of hemolytic toxicity caused
by PQ in the G6PDd population.The new knowledge generated would provide rational bases for
controlling toxicity of PQ and designing 8AQ analogs with better safety and therapeutic profiles.
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CHAPTER 1
DRUG-INDUCED OXIDATIVE HEMOLYTIC ANEMIA

1.1. INTRODUCTION
The pathophysiological and toxic manifestations caused due to treatment with a drug in the
blood cells are clinically referred as drug-induced hematologic disorders. The drug-induced
hematologic disorders can affect all types blood cells including leukocytes, erythrocytes, and
platelets. Reduction in all three cell-types with a hypoplastic bone marrow, due to a drug-treatment
is referred as drug-induced aplastic anemia. The reduction in leukocytes alone due to a drugtreatment is known as drug-induced agranulocytosis. The decrease in platelet counts due to drug
exposure is called drug-induced thrombocytopenia (Kamakshi 2014). Decrease in hematocrit
primarily due to hemolytic reactions or an accelerated removal of red blood cells is known as
hemolytic anemia.
Drug treatments can affect erythrocytes by causing various hemolytic anemias, comprising
drug-induced immune hemolytic anemia, drug-induced megaloblastic anemia and drug-induced
oxidative hemolytic anemia (Kamakshi 2014). Hemolysis is the removal of damaged erythrocytes
from the circulation before their normal life span (120 days). Hemolysis can remain asymptomatic
for a lifetime and most often represents as anemia when erythrocytosis cannot balance the rate of
erythrocytes destruction. The clinical manifestation of hemolytic anemia are dark urine.
cholelithiasis, isolated reticulocytotic or jaundice (Dhaliwal et al. 2004).
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In drug-induced immune hemolytic anemia, the body generated immunoglobin G or
immunoglobulin M (IgM) (or both) against the erythrocytes, and these antibodies bind to antigens
on the surface of erythrocytes. The binding of antibodies and antigens triggers the destruction of
erythrocytes via the complement and mononuclear phagocytic systems (Garratty 2012). Th drugs
which directly or indirectly affect DNA synthesis cause megaloblastic hemolysis. In this type of
hemolytic anemia, the development of megaloblasts, the precursor of erythrocytes, is abnormal in
bone marrow (Scott and Weir 1980). The drugs which produce oxidative stress and have potential
to undergo redox cycling cause drug-induced oxidative hemolytic anemia. Such type of anemia is
commonly seen in a genetic condition of glucose 6 phosphate dehydrogenase (G6PD) enzyme
deficiency (Winterbourn 1985; Fibach and Rachmilewitz 2008).
Drug-induced hemolytic anemia can be intravascular or extravascular. In intravascular
hemolysis, the destruction of erythrocytes occurs in the circulation, and the content of erythrocytes
is released into the vascular compartment. The common causes of intravascular hemolysis are
complement fixation, immune complex deposition, infectious agent, membrane damage and
membrane trauma due to oxidative damage. The second type of hemolysis is extravascular
hemolysis and is relatively more common than intravascular hemolysis. In extravascular
hemolysis, the damaged erythrocytes that contain membrane alterations are eliminated from the
circulation by macrophages of the liver and spleen (Dhaliwal et al. 2004; Kamakshi 2014).

1.2. GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY
G6PD deficiency is the most common enzymopathy with more than 400 million cases in
worldwide and is frequent in malaria endemic countries (Youngster et al. 2010; Mason et al. 2007).
G6PD deficiency is an X-linked hereditary disorder caused due to a mutation in G6PD gene
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(Cappellini and Fiorelli 2008; Youngster et al. 2010). G6PD deficiency has more than 400 allelic
variants (Nkhoma et al. 2009), and PQ causes hemolysis in all variants (Mason et al. 2007). G6PD
enzyme deficiency is highly prevalent in Africa, southern Europe, the middle east, southeast Asia,
and the central and southern Pacific islands. However, due to migrations, this deficiency is
relatively prevalent in North and South America and parts of northern Europe (Cappellini and
Fiorelli 2008). The clinical manifestations of hemolytic toxicity depend mainly on the amount of
oxidative stress and severity of the patient’s G6PD genetic defect (Cappellini and Fiorelli 2008;
Kamakshi 2014). The most common G6PD variants are the Mediterranean variant and African
variant. A Mediterranean variant is the most severe G6PDd variant and is mainly found in Europe,
west and central Asia, and northern India. African variant is the mildest variant. This variant is
predominant in sub-Saharan Africa and African-Americans. (Cappellini and Fiorelli 2008)
G6PD enzyme participates in the pentose phosphate pathway, which is the sole source for
production of NADPH, glutathione recycling in erythrocytes, and is essential for the function of
catalase (Figure 1.1) (Nkhoma et al. 2009; Mason et al. 2007; Cappellini and Fiorelli 2008; Judith
Recht 2014). NADPH, GSH, and catalase constitute primary antioxidant defense system in human
erythrocytes (Judith Recht 2014). The G6PDd erythrocytes have limited capability to regenerate
NADPH and recycle GSH. Oxidative stress may exhaust the cellular GSH in G6PDd erythrocytes
due to compromised efficiency to produce NADPH. The later events may cause cellular and
molecular changes in erythrocytes, which may lead to hemolytic anemia in the G6PDd population
treated with drugs causing oxidative stress (Mason et al. 2007).
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Figure 1.1: Role of glucose 6 phosphate dehydrogenase (G6PD) and other antioxidant enzymes
against oxidative stress. NADP- Nicotinamide adenine dinucleotide phosphate. NADPHNicotinamide adenine dinucleotide phosphate hydrogen. (Youngster et al. 2010)
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1.3. OXIDATIVE STRESS IN ERYTHROCYTES
1.3. 1. Reactive oxygen species
The oxidative status of cells is regulated by the equilibrium between pro-oxidants and
antioxidants. Reductants donate electrons, and oxidants accept electrons. Prooxidants act as
reactive oxygen species (ROS) and are classified into nonradicals and radicals. The radicals have
at least an unpaired electron, which is responsible for high reactivity. Radicals either accept or
donate an electron to gain stability. The radicals react rapidly with other molecules and thus have
a short half-life. The most common radicals in biological systems are alkoxyl radicals (RO˙),
hydroxyl radical (OH˙), nitric oxide radical (NO˙), superoxide ion radical (O˙ - 2), and one form of
singlet oxygen (1O2). The non-radical ROS life span varies from seconds to hours. Non-radical
reactive oxygen species include the aldehydes, hypochlorous acid (HClO), hydrogen peroxide
(H2O2), organic peroxides, ozone (O3) and molecular oxygen (O2) (Fibach and Rachmilewitz 2008;
Winterbourn 1985). The properties of common ROS are described in Table 1.1.
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Table 1.1: Characteristics of common reactive oxygen species (ROS) (Winterbourn 1985).
ROS
Hydrogen
peroxide (H2O2)

Characteristics
Oxidizing Compound,
Permeable to membranes
Cause lipid peroxidation
React with heme protein and thiols

Hypochlorous acid Oxidizing Compound
(HClO)
Permeable to membranes
Forms protein crosslinks
Selectively react with thioester and thiols
Singlet oxygen
(1O2)
Hydroxyl radical
(OH˙)
Superoxide
(O˙- 2)

Excited state and high-energy form of oxygen,
React with majority of biomolecules
Lead to protein denaturation, lipid peroxidation, and enzyme inactivation
Highly reactive with majority of biomolecules
Form hydroxyl radical via Fenton reaction
Limited membrane permeability and biological reactivity
Oxidizes and reduces hemoglobin
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1.3.2. Antioxidant enzymatic system
The primary function of endogenous antioxidative enzymes is to maintain the redox
balance during oxidative stress in the cells/erythrocytes. The main endogenous antioxidative
enzymes are superoxide dismutase (SOD), glutathione peroxidase (GPx), glutathione reductase
(GR) and catalase (CAT) in the erythrocytes. All these enzymes provide protection against ROS
via scavenging superoxide radicals and hydrogen peroxide, changing them to less reactive species
(Figure 1.2. and 1.3) (Pandey and Rizvi 2010; Fibach and Rachmilewitz 2008).
SOD catalyzes the conversion of superoxide anion (O-2) to hydrogen peroxide (H2O2). As
mentioned earlier, H2O2 is ROS and not a radical, though it is quickly converted to hydroxyl radical
(•OH) by Fenton reaction. The hydroxyl radicals are extremely reactive with many biomolecules
and are responsible for most of the cellular damage. SOD is one of the most important endogenous
antioxidant enzymes and protects cells from ROS (Pandey and Rizvi 2010; Fibach and
Rachmilewitz 2008; Winterbourn 1985).
Glutathione peroxidase (GPx) counteracts hydrogen peroxide (H 2O2) by using hydrogens
from two GSH (reduced glutathione) molecules and forming two water molecules and one GSSG
(oxidized glutathione). The enzyme glutathione reductase (GR) then recycles GSH from GSSG
using NADPH as a source of hydrogen (Pandey and Rizvi 2010; Fibach and Rachmilewitz 2008).
Catalase enzyme is another vital part of the enzymatic defense system in the cell. Catalase
is the most active enzyme present in nature (Pandey and Rizvi 2010). The enzyme shows high
affinity for H2O2 and thus degrade H2O2 into water rapidly before it can diffuse to the other parts
of erythrocytes. Catalase offers highly energy efficient mechanism to remove H 2O2. Therefore,
during energy deprivation environment, catalase neutralize H 2O2 in an energy efficient manner
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which results in the net gain of reducing equivalents and cellular energy. Hence, the activity of
catalase is a critical biomarker of oxidative stress (Pandey and Rizvi 2010; Fibach and
Rachmilewitz 2008)
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Figure 1.2: Neutralization of reactive oxygen species by the endogenous antioxidant system in
erythrocytes (Fibach and Rachmilewitz 2008).
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Figure 1.3: Combined action of the endogenous antioxidant system (blue) to detoxifies reactive
oxygen species (red) by endogenous in erythrocytes (Fibach and Rachmilewitz 2008). O-2:
Superoxide anion; H2O2: Hydrogen peroxide; SOD: Superoxide dismutase; GPx: Glutathione
peroxidase; GR: Glutathione reductase; GSH: Reduced glutathione; GSSG: Oxidized
glutathione.
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1.3.3. Oxidation of hemoglobin
Hemoglobin is a solid source of generation of superoxide radicals in erythrocytes. There is
a transfer of an electron between the heme iron and oxygen in oxygenated hemoglobin. When
hemoglobin is oxygenated, the heme iron stays in the Fe2+ ferrous state. Though when hemoglobin
auto-oxidizes, methemoglobin and superoxide radicals are formed. In normal physiological
condition, the formation of methemoglobin (approximately, 3%) produces superoxide
continuously and subsequently generates hydrogen peroxide and oxygen as byproducts of
dismutation reaction. Hence, normal erythrocytes have a huge amount of the reducing enzyme
SOD. To restore hemoglobin function, methemoglobin is reduced by the NADH methemoglobin
reductase and NADH methemoglobin reductase (Gordon-Smith 1980; Winterbourn 1985).
Due to excessive oxidation of hemoglobin, the globin protein of hemoglobin is denatured,
condensed and precipitated. These denatured globin proteins in the hemoglobin are called, “heinz
bodies.” The interaction between the xenobiotic (drug having oxidation properties) and
hemoglobin is the crucial process, which is characterized by methemoglobin and heinz body
formation and both of them are important biomarkers of oxidative hemolytic anemia (GordonSmith 1980; Winterbourn 1985).

1.3.4. Oxidation of erythrocytes membrane
The membranes in erythrocytes contain lipid bilayer. Due to the oxidative stress, the lipid
peroxidation occurs. Lipid peroxidation, a free-radical chain reaction is augmented by ROS.
During this process, unstable carbon radicals are generated from the fatty acids and rearrange to
produce short alkanes and conjugated dienes. These short alkane and conjugated dienes then react
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oxygen to form peroxyl radicals, and through abstraction of hydrogen abstraction, lipid
hydroperoxides are formed. The oxidation products are highly reactive and undergo for further
oxidation and form secondary oxidation products like 4-hydroxy-2-,3-trans-nonenal (HNE),
malondialdehyde (MDA), or isoprostanes. The second oxidation products can lead to form protein
cross-linking and thus denatures the protein. Thus, the formation of MDA is frequently used as a
biomarker to examine the oxidative damage on lipids (Gordon-Smith 1980; Fibach and
Rachmilewitz 2008; Pandey and Rizvi 2010).

1.3.5. Eryptosis
The suicidal death of erythrocytes is called eryptosis. It is a coordinated signaling pathway
of certain events, which cause disposal of defective erythrocytes. As erythrocytes do not contain
mitochondria and nucleus, they are devoid of the classical apoptotic pathway and apoptotic
characteristics such as mitochondrial depolarization and condensation of nuclei. Also, the
signaling pathways, which lead to eryptosis, are different from classical pathways of apoptosis
(Figure 1.4).

However, eryptosis shares some traits of apoptosis-like cell shrinkage, cell

membrane blebbing, and exposure of phosphatidylserine (PS) on the cell surface. Moreover, like
apoptosis, in eryptosis, the defected cells are engulfed and degraded by macrophages (Lang et al.
2012). Eryptosis is commenced by complex signaling pathways, which are comprised of: 1)
increase in intracellular free calcium ion concentration, ceramide and, prostaglandin-E2 (PGE2);
2) activation of caspases, kinases, ionic channels and calpain protease and 3) externalization of
phosphatidylserine to the erythrocytes surface. Eryptosis can be caused due to osmotic shock,
mechanical damage of erythrocytes and agents that induce energy depletion or generate oxidative
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stress. The elevation of eryptosis is correlated with metabolic disease, genetic disorders and
bacterial and viral infections (Aguilar-Dorado et al. 2014).
Different eryptosis stimulators including oxidative stress, energy depletion, and
hyperosmotic shock cause activation of Ca2+ permeable non-selective cation channels and trigger
the intake of Ca2+ in erythrocyte. The increase in intraerythrocytic Ca2+ activates protease calpain,
a cysteine endopeptidase, which degrades protein and ultimately promotes cell membrane
blebbing. Moreover, the increment in cytosolic Ca2+ stimulates degeneration of phospholipid
asymmetry of the cell membrane and causes phosphatidylserine exposure at the outer membrane
leaflet of the erythrocyte. Externalization of PS is a signal to circulating macrophages to come and
engulf the affected cells (Lang et al. 2006; Lang and Lang 2015).

13

Figure 1.4: Major events of eryptosis pathway (Lang and Lang 2015).
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1.3.6. Pathway of oxidative stress in erythrocytes
In, erythrocytes the hemoglobin is converted to methemoglobin via auto-oxidation or in
the presence of xenobiotic (usually drug which has redox and oxidative potential). During
formation of methemoglobin, superoxide anions are formed. SOD converts superoxide anions to
hydrogen peroxide, and hydrogen peroxide is detoxified via enzyme catalase. Apart from SOD
and catalase, other endogenous antioxidants present in erythrocytes take care of ROS. However,
if these endogenous antioxidants failed to detoxify ROS, damage to macromolecules, like lipid
peroxidation, denaturation of hemoglobin and formation of heinz body and protein cross-linking
occur which is irreversible and this leads to the lysis of erythrocytes (Pandey and Rizvi 2010;
Gordon-Smith 1980; Winterbourn 1985). The pathway of oxidative stress leading to hemolytic
toxicity is described in Figure 1.5.
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Figure 1.5: Pathway leading to hemolysis caused by oxidative stress (Pandey and Rizvi 2010).
The reactive oxygen species (red) are detoxified through the endogenous antioxidant system
(blue). If the endogenous antioxidant system is failed to neutralize reactive oxygen species,
macromolecule damage occurs. O-2: Superoxide anion; H2O2: Hydrogen peroxide; SOD:
Superoxide dismutase.
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1.4. DRUGS ASSOCIATED WITH OXIDATIVE HEMOLYTIC ANEMIA
1.4.1. Ascorbic acid
Ascorbic acid (Figure 1.6) is given at higher doses to treat severe deficiency such as scurvy.
High doses of ascorbic acid aid in the prevention of colds, the improved wound healing, and
treatment of cancer (Vilter 1980). Literature reports incidents of hemolysis after higher doses of
ascorbic acid in G6PDd erythrocytes (Rees et al. 1993; Udomratn et al. 1977; Huang et al. 2014).
In vivo studies were done to investigate the effect of higher doses of ascorbic acid on G6PDd
human erythrocytes. At larger doses, ascorbic acid-induced hemolysis of G6PDd human
erythrocytes (Udomratn et al. 1977). Though at therapeutic dosages, there are no confirmations to
disregard the use of ascorbic acid in patients with a G6PDd population (Youngster et al. 2010).
Literature also reports oxidative hemolysis caused by higher doses of ascorbic acid in
patients having normal erythrocytes with no genetic defect (Ibrahim et al. 2006) and with
hemoglobinopathies like sickle cell anemia and thalassemia (Arruda et al. 2013). Contrast to
hemolytic incidences of ascorbic acid; reports also showed that ascorbic acid decreased the
phenylhydrazine-induced oxidative hemolysis by inhibiting methemoglobin and heinz bodies
formation caused by phenylhydrazine in erythrocytes (Claro et al. 2006; Biswas et al. 2005). Thus,
the controversial effect of ascorbic acid is observed on hemolysis, and the exact mechanism and
clinical significance of these findings are still unclear.
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Figure 1.6: Structure of Ascorbic acid

1.4.2. Dapsone
Dapsone (DDS), an antibacterial and antiprotozoal agent, is used for the treatment of
various disease conditions including dermatitis herpetiformis, Pneumocystis pneumonia in
acquired immunodeficiency syndrome (AIDS) patient, leprosy, malaria and inflammation (Wolf
et al. 2000; Ganesan et al. 2010). Several clinical reports confirm the hemotoxicity of DDS (Deps
et al. 2012; Cha et al. 2016; Pamba et al. 2012; Barclay et al. 2011; Mitsides et al. 2014).DDS
metabolites produced in the liver are believed to cause hemotoxic reactions (Figure 1.7). Earlier
studies on the CYP-mediated metabolism of DDS had shown that CYP2C9, CYP2C19, CYP2E1,
and CYP3A4, are mainly involved in the metabolism of DDS (Li et al. 2003; Ganesan et al. 2010).
Dapsone causes hemotoxicity in normal as well as G6PDd populations and the mechanisms
seem to induce changes to the membranes of erythrocyte membrane (McMillan et al. 2005). ROS
is produced this drug, induces binding of oxidized and denatured hemoglobin to the cytoskeleton
membrane of erythrocytes. These oxidative changes in the erythrocytes’ membrane lipids have
been demonstrated to accelerate the removal of the damaged erythrocytes by macrophages, leading
to hemolytic injury (McMillan et al. 2005).
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Dapsone hydroxylamine (DDSNOH), is a potent hemotoxic metabolite of DDS (Grossman
and Jollow 1988; McMillan et al. 1995) and has been linked to hemolytic toxicity of DDS in
several in vitro and in vivo studies (Mitra et al. 1995; McMillan et al. 1995; Grossman et al. 1995;
Grossman et al. 1992; McMillan et al. 1998). CYP2C9 and CYP2C8 isoforms of CYP enzymes
cause the formation of dapsone hydroxylamine (Ganesan et al. 2010). DDSNOH induces
methemoglobin, generates oxidative stress in human erythrocytes (Kramer et al. 1972;
Albuquerque et al. 2015). It further depletes GSH, forms disulfide-linked hemoglobin polymers
and disulfide-linked hemoglobin adducts on certain membrane skeletal proteins in rat and human
erythrocytes (Grossman et al. 1992; McMillan et al. 1995). The literature suggests that the
hemotoxicity associated with DDS depends on the metabolism of DDS, though exact metabolism
and hemotoxic pathways of DDS are still unclear.

Figure 1.7: Metabolism of DDS to DDSNOH
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1.4.3. Metformin
Metformin (Figure 1.8.A) is an antidiabetic drug and, is used in first-line therapy for type
II diabetes. There have been 14 million Americans which were administered metformin between
2010 and 2012, indicating the widespread use of metformin among the diabetic population
(Ruggiero et al. 2016). Metformin-induced hemolytic anemia in G6PDd patients have been
reported in the literature (Ruggiero et al. 2016; Meir et al. 2003; Blum et al. 2011; Packer et al.
2008; Kirkiz et al. 2014; Kamakshi 2014). Though the metformin-induced hemolysis is rare, and
metformin is not incorporated in the list of drugs unsafe in G6PDd population, and it still is
important to consider seriously. There is not known mechanism of metformin-induced hemolysis
and a definitive association between G6PD enzyme activity, and metformin-induced hemolytic
anemia is not known (Ruggiero et al. 2016). In practice, it would be not practical to screen patients
started on metformin for G6PD deficiency; though a patient with known G6PD deficiency should
be observed carefully, or prescription of metformin in patients with known G6PD deficiency need
to be avoided (Ruggiero et al. 2016). No studies has been to understand the mechanism of
hemotoxicity associated with metformin.

1.4.4. Methylene blue
Methylene blue (methylthioninium chloride) (Figure 1.8.B) is a compound with multiple
uses. It is mainly used for the treatment of methemoglobinemia induced by drugs. In addition, it is
used for the treatment of various infections and poisoning in vivo. In vitro, it is used as a dye to
stain tissues, bacterial cells, and DNA (McDonagh et al. 2013). Methylene blue is an effective
therapy to reduce methemoglobin back to hemoglobin. However, methylene blue is linked with
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adverse hemolysis reactions in G6PDd individuals. Thus, methylene blue is contraindicated or
advised precaution for use in G6PDd individuals due to a risk of hemolytic anemia (Youngster et
al. 2010; Kamakshi 2014; McDonagh et al. 2013).
Methylene blue causes reduction in methemoglobinemia via biliverdin reductase B
(BLVRB) enzyme (Skold et al. 2011; Curry 1982; Wright et al. 1999). Methylene blue is reduced
to leukomethylene blue by BLVRB enzyme, and during this reduction, BLVRB enzyme accepts
electrons from NADPH (Curry 1982). Leukomethylene blue acts as an electron donor and reduces
methemoglobin back to hemoglobin and converts to methylene blue in a redox cycle reaction
(Curry 1982; Wright et al. 1999). On the contrary, methylene blue is an oxidizing agent; it can
cause methemoglobinemia at high concentrations. Methylene blue causes hemolysis by oxidizing
hemoglobin, oxidizing GSH to GSSG and forming heinz bodies (Sills and Zinkham 1994; Kelner
and Alexander 1985). However, the exact pathway of methylene blue-induced hemolysis is still
unknown.
The mechanism of action of methylene blue to reduced methemoglobin back to
hemoglobin depends on the intracellular capacity for NADP/NADPH recycling of the
erythrocytes. The pentose phosphate pathway is the only source of NADPH in erythrocytes,
methylene blue treatment to reduce methemoglobin back to hemoglobin relies on G6PD enzyme
activity. Moreover, methylene blue has been linked to exacerbating oxidative stress in G6PDd
erythrocytes. Thus, methylene blue is an inappropriate treatment option for methemoglobinemia
in G6PD-deficient individuals (McDonagh et al. 2013).
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Figure 1.8: Structure of (A) metformin and (B) Methylene blue.
1.4.5. Nitrofurantoin
Nitrofurantoin (NFT) is the drug of choice for treatment and prophylaxis of acute
uncomplicated lower urinary tract infections because of minimum resistance, the lower tendency
of collateral damage and high efficacy (Colgan and Williams 2011; Gupta et al. 2011; Shakti and
Veeraraghavan 2015). NFT also causes severe hemolytic anemia in glucose-6-phosphate
dehydrogenase (G6PD) deficient populations. This limits the use of NFT for these patients (Gait
1990; Shakti and Veeraraghavan 2015). Moreover, evidence shows the hydroxylation of NFT
(Jonen 1980) and formation of aminofurantoin metabolite of NFT in rat (Aufrere et al. 1978). In
addition, aminofurantoin, a reductive metabolite of NFT is detected in human urine as well
(Hoener and Patterson 1981). Thus, aminofurantoin is the only known human metabolite of NFT.
However, recent data suggest that nitrofurantoin is metabolized through CYP450 system and
generate 1-aminohidantoin in rat (Aracena et al. 2014). These data suggest that metabolism of NFT
occurs through both reductive and oxidative pathway. However, the knowledge about the
pathways for metabolism of NFT, namely type of CYP isoforms and identity of the metabolites,
is still unclear and incomplete.
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A preliminary study with normal blood cells showed that NFT increased methemoglobin
formation and hydrogen peroxide generation, whereas cellular levels of GSH and ATP were
decreased (Dershwitz et al. 1985). NFT reversibly inhibits glutathione reductase (GR) in rat
hemolysates, hepatocytes and human hemolysates (Buzard et al. 1960; Rossi et al. 1988). The
redox cycling and nitro reduction ability of NFT is known to be associated with its hepatic and
pulmonary toxicity. The one electron reduction of the 5-nitro group in NFT, produces nitro radical
anions and furthermore generates superoxide, hydrogen peroxide (H 2O2) and highly reactive
hydroxyl radical (Figure 1.9). Thus, the potential of NFT for the formation of ROS seems to cause
cytotoxicity but is not the only factor to cause toxicity (Minchin, Ho, and Boyd 1986; Wang et al.
2008). The mechanism of hemolytic toxicity of NFT in G6PDd patient is still unknown, but in
normal erythrocytes, the challenge with NFT is that it increases MtHb formation and H 2O2
generation with decreases in cellular levels of GSH and ATP (Dershwitz et al. 1985). However,
no investigations have been done in G6PDd erythrocytes in vitro and in vivo to follow the
hemolytic response and mechanism for the hemolytic toxicity of NFT. Thus, the hemolytic
mechanism induced by NFT is still not clear and unknown.
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Figure 1.9: Redox cycling of NFT and generation of reactive oxygen intermediates (Wang et al.
2008; Gupta et al. 2011)
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1.4.6. Nalidixic acid
Nalidixic acid (Figure 10.A) is an antibacterial belonging to the quinolone class. The likely
adverse effect of nalidixic acid in general population is hemolytic anemia. There were three
reported cases of hemolysis in G6PDd individuals induced by nalidixic acid and accordingly there
is a caution concerning the use of nalidixic acid in G6PDd patients (Youngster et al. 2010).
The photosensitized hemolytic lysis caused by nalidixic acid was investigated by
(Fernandez and Cardenas 1990; Fernandez et al. 1987). The nalidixic acid-induced photohemolysis was oxygen-dependent. The effects of numerous antioxidants and hydroxyl radical
scavengers on nalidixic-induced photo-hemolysis indicated a photo-oxidative step. Furthermore,
it was found that the nalidixic acid was the reason of hemolysis, yet the photoproducts for nalidixic
acid showed a greater potential of photo-hemolysis rather than nalidixic acid itself (Fernandez et
al. 1987; Fernandez and Cardenas 1990). However, the exact mechanism photosensitized
hemolytic lysis caused by nalidixic acid is still not complete.

1.4.7. Phenazopyridine
Phenazopyridine (Figure 10.B) is an azo dye and has analgesic properties. It is frequently
given with antibacterial therapy for urinary tract infection as it aids to relieve pain and discomfort
(urgency, frequency) before antibacterial controls the infection. This drug is available through
prescription as well as over the counter (Cornwell and Bartek 1996).
Literature shows that phenazopyridine caused severe hemolysis in G6PDd patients (Tishler
and Abramov 1983; Galun et al. 1987). Phenazopyridine has been associated with
methemoglobinemia, heinz body formation in erythrocytes in patients with overdose or having
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renal insufficiency (Cornwell and Bartek 1996; Yu et al. 2011; Noonan et al. 1983; Terrell et al.
1988). Though it should be noted that hemolysis has been linked with patients with no G6PDd too
(Cornwell and Bartek 1996; Yu et al. 2011; Youngster et al. 2010; Terrell et al. 1988). The
hemotoxicity of phenazopyridine is linked with its metabolism. A metabolite phenazopyridine
namely, 2,3,6-triaminopyridine, autoxidizes at neutral pH and produces superoxide radical and
hydrogen peroxide and thus may be responsible for hemolytic anemia caused by phenazopyridine
(Munday and Fowke 1994). The knowledge of the mechanism associated with phenazopyridine
induced hemolysis is not clear.

Figure 1.10: Structure of (A) nalidixic acid and (B) phenazopyridine.
1.4.8. Primaquine
Primaquine (PQ), belongs to a drug class 8-aminoqinoline (8-AQ) and is a potential
antiprotozoal agent. It is mainly used for prophylaxis and treatment of malaria. PQ is the only drug
approved by FDA, and acts against the hard-to-kill liver stage of Plasmodium vivax and P. oval
and used to prevent malaria relapse (Ashley et al. 2014; Tekwani and Walker 2006). Relapses are
significantly responsible for the morbidity in P. vivax and P. ovale malaria (Leslie et al. 2016). PQ
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also acts against mature P5 P. falciparum gametocytes and thus WHO recommends PQ for
prevention of malaria transmission.
PQ causes severe hemolytic reactions in individuals with a genetic deficiency of glucose6-phosphate dehydrogenase (G6PD) (Ashley et al. 2014) and the G6PD deficiency was discovered
due to PQ-induced hemotoxicity in 1950. The understanding of PQ metabolism has been greatly
expanded in the last six years. The metabolism of PQ mainly depends on two metabolizing
enzymes, namely CYP 2D6 and MAO-A (Figure 1.11). The in vitro studies of PQ, showed that all
CYP isoforms (CYP 2D6, MAO-A, CYP 2C19, and CYP 3A4) have capability to metabolize
primaquine to some extent (Pybus et al. 2012). The phenolic metabolites related with redox cycling
(Vasquez-Vivar and Augusto 1992) were mainly the products of CYP 2D6 metabolism (Pybus et
al. 2012; Fasinu et al. 2014). Further knockout mice studies demonstrated that the formation
phenolic metabolites of PQ was reduced in CYP 2D knockout mice (Potter et al. 2015).The MAOA enzyme causes the formation of a primaquine aldehyde species carboxyprimaquine, which is
the most abundant plasma metabolite of PQ in the humans (Pybus et al. 2012; Fasinu et al. 2014).
Several studies have been done to understand the hemolytic toxicity of the PQ in vitro and
in vivo (Vasquez-Vivar and Augusto 1992, 1994; Bolchoz et al. 2001; Bolchoz et al. 2002b;
Bolchoz et al. 2002a; Bowman et al. 2004; Bowman et al. 2005b; Bowman et al. 2005a; Ganesan
et al. 2009; Ganesan et al. 2012). It is well established that the hemolytic anemia and efficacy of
PQ is hepatic metabolism-dependent (Ganesan et al. 2012; Ganesan et al. 2009; Fasinu et al. 2014;
Pybus et al. 2012; Pybus et al. 2013). The hemotoxic effect of PQ in the presence of human liver
microsomes (HLM), mouse liver microsomes (MLM) and recombinant human-CYPs isoforms in
normal and G6PDd human erythrocytes was analyzed (Ganesan et al. 2009; Ganesan et al. 2012).
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The studies showed that in the presence of HLM, PQ-induced methemoglobin (MtHb) formation,
reactive oxygen species (ROS) generation, and depletion in thiols in human erythrocytes (Ganesan
et al. 2009; Ganesan et al. 2012). Multiple CYP isoforms (CYP1A2, CYP2E1, CYP2B6, CYP2D6,
and CYP3A4) were found to mediate the metabolism of PQ and cause PQ-associated hemotoxicity
in human erythrocytes (Ganesan et al. 2009). Recent studies revealed that the production of 5hydroxy primaquine and other phenolic metabolites of PQ depend on of CYP 2D6-mediated
metabolism (Fasinu et al. 2014; Pybus et al. 2012; Pybus et al. 2013; Potter et al. 2015). However,
the exact hemotoxic mechanism due to PQ in erythrocytes is still unclear (Marcsisin et al. 2016).
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Figure 1.11: Metabolism of PQ via CYP2D6 and MAO-A pathway. cPQ: carboxyprimaquine,
(2HPQ): 2-hydroxyprimaquine, 3HPQ: 3-hydroxyprimaquine, 4HPQ: 4-hydroxyprimaquine, 5HPQ: 5-hydroxyprimaquine and 5,6-OQPQ: 5,6-orthoquinone-primaquine.
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1.4.9. Rasburicase
Rasburicase is a recombinant urate oxidase used for the prevention and treatment of
hyperuricemia associated with hematological malignancies (Pui 2002; Goth 2008). Rasburicase
caused hemolytic anemia in G6PDd patients. Rasburicase has oxidizing potential and converts uric
acid with high affinity into allantoin, which is removed by the kidneys. During this conversion, a
high concentration of hydrogen peroxide is generated which might is responsible for the hemolysis
in G6PDd and catalase enzyme deficiency (Goth 2008; Ibrahim et al. 2017). Moreover, due to the
oxidizing property of rasburicase, the ferrous form of iron in erythrocytes is converted to ferric
form resulting in the formation of methemoglobin, which makes the heme component incapable
of carrying oxygen (Ibrahim et al. 2017). Rasburicase induced robust methemoglobin formation
in G6PDd and catalase deficient patient and thus methemoglobin is used as a biochemical marker
in laboratories to determine hemolysis caused by this drug (Elinoff et al. 2011; Cheah et al. 2013;
Ng et al. 2012; Bucklin and Groth 2013; Ibrahim et al. 2017).

1.4.10. Sulfacetamide
Sulfacetamide is a sulfonamide and have anti-infectious properties. Currently, it is
primarily used in topical formulations. Sulfacetamide has the theoretical potential to induce
hemolysis in G6PDd patients, but the literature search showed no reported cases. It seems that
sulfacetamide can be used safely in G6PDd patients in topical formulations (Youngster et al.
2010).

1.4.11. Sulfamethoxazole
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Sulfamethoxazole is used sulfonamide antibacterial and comes in combination with
trimethoprim. The combination of trimethoprim and sulfamethoxazole is called cotrimoxazole.
Several reports suggest the hemolysis caused trimethoprim-sulfamethoxazole or sulfamethoxazole
alone in G6PDd erythrocytes (Chisholm-Burns et al. 2010; Chan and Wong 1975; Reinke et al.
1995; Chan 1997; Chan 1972; Owusu 1972). However, in some clinical studies the effect of
trimethoprim-sulfamethoxazole or sulfamethoxazole alone in G6PDd erythrocytes is inconclusive
(Chan and McFadzean 1974; Lexomboon and Unkurapiana 1978).

1.4.12. Sulfanilamide
Sulfanilamide is a short-acting sulfonamide with antibacterial properties (Barkan and
Goldsmith 1946; Youngster et al. 2010). Several clinical reports suggest that sulfanilamide induces
hemolysis in G6PDd erythrocytes and the hemolysis is the cause of oxidative properties and redox
potential of this drug (Ali et al. 1999; Barkan and Goldsmith 1946; Naiman 1964; Heeres and
Zondag 1961). The oxidant and reduced forms of sulfanilamide have antibacterial potential.
Moreover, the reduction and oxidation of sulfanilamide are reversible (Barkan and Goldsmith
1946). In a study, Ali et al. suggested that sulfanilamide caused concentration-dependent GSH
depletion selectively in G6PDd erythrocytes as compared to normal erythrocytes (Ali et al. 1999).
Early reports suggest the hemolysis in G6PDd erythrocytes individuals, however, the dose is four
times higher than the therapeutic dose. No hemolysis reports were found at a therapeutical dose of
sulfanilamide in G6PDd population (Youngster et al. 2010).
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Figure 1.12: Structure of (A) sulfacetamide, (B) sulfamethoxazole and (C) sulfanilamide.

1.5. CONCLUDING REMARKS
The detrimental effects of oxidative stress are caused due to the uncontrolled generation of
ROS. ROS play a vital role in hemolysis initiation (Fibach and Rachmilewitz 2008). Drugs that
has redox potential and oxidative properties are capable of forming methemoglobin. During
methemoglobin formation, superoxide radical and ions are produced (Gordon-Smith 1980;
Winterbourn 1985). To detoxify this ROS the endogenous antioxidant enzymes like SOD, GR,
GPx and catalase play a crucial role. However, if these endogenous antioxidants are not able to
take care of ROS, lipid peroxidation, protein crosslinking and denaturation occurs (Fibach and
Rachmilewitz 2008; Pandey and Rizvi 2010). These biochemical, molecular and cellular
parameters which are affected and modified during hemolysis caused by oxidative stress serve
excellent biomarkers to examine the extent of oxidative damage, and aid to assess hemolysis
related changes (Pandey and Rizvi 2010).
The knowledge associated with the mechanism and pathways of drug-induced oxidative
hemolysis is limited. Further studies, to identify early and late (eryptotic) hemotoxic marker and
studies to understand the oxidative hemotoxic pathway in the erythrocytes are needed to be done.
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The knowledge generated by these studies can be used to build a strategy to mitigate drug-induced
oxidative hemolysis.
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CHAPTER 2
EVALUATION OF EARLY AND LATE BIOCHEMICAL AND CELLULAR CHANGES
TRIGGERED BY PRIMAQUINE METABOLITES IN NORMAL AND GLUCOSE-6PHOSPHATE DEHYDROGENASE DEFICIENT HUMAN ERYTHROCYTES

2.1. INTRODUCTION
Currently, primaquine (PQ), an 8-aminoquinoline (8-AQ), is the sole FDA-approved drug,
which acts against the hard-to-kill hypnozoites stage of Plasmodium vivax and P. ovale and used
to prevent malaria relapse (Ashley et al. 2014; Tekwani and Walker 2006). Relapses are significant
contributors to infection and morbidity in P. vivax and P. ovale malaria (Leslie et al. 2016). PQ
also acts against mature P5 P. falciparum gametocytes and thus WHO recommends PQ for
prevention of malaria transmission (Tekwani and Walker 2006; Ashley et al. 2014). 8-AQs also
have a potential therapeutic use for treatment of other protozoal infections namely, leishmaniasis
and trypanosomiasis as well as pneumocystis infections (Tekwani and Walker 2006). However,
PQ causes severe hemolytic reactions in individuals with a genetic deficiency of glucose-6phosphate dehydrogenase (G6PD) (Ashley et al. 2014). G6PD deficiency is the most common
enzymopathy with more than 400 million cases worldwide and is frequent in malaria endemic
countries (Mason et al. 2007; Youngster et al. 2010). PQ-induced hemotoxicity in G6PD deficient
(G6PDd) population precludes the use of PQ for much- needed malaria control and elimination
efforts and necessitates the development of 8-AQ analogs with better safety.
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Numerous studies have explored the hemolytic toxicity of the PQ in vitro and in vivo
(Vasquez-Vivar and Augusto 1992, 1994; Bolchoz et al. 2001; Bolchoz et al. 2002b; Bolchoz et
al. 2002a; Bowman et al. 2004; Bowman et al. 2005b; Bowman et al. 2005a; Ganesan et al. 2009;
Ganesan et al. 2012). It is well established that the hemolytic anemia and efficacy of PQ is hepatic
metabolism-dependent (Ganesan et al. 2012; Ganesan et al. 2009; Fasinu et al. 2014; Pybus et al.
2012; Pybus et al. 2013). Recent studies revealed that the production of 5-hydroxy-primaquine (5HPQ) and other phenolic metabolites of PQ depend on of CYP 2D6-mediated metabolism (Fasinu
et al. 2014; Pybus et al. 2012; Pybus et al. 2013; Potter et al. 2015). The 5-HPQ is capable of redox
cycling back and forth to the corresponding quinone-imine. The 5-HPQ and corresponding
quinone-imine species, in the presence of water, form the stable 5,6-orthoquinone primaquine (5,6OQPQ) (Figure 2.1) (Marcsisin et al. 2016).
Previous studies showed that PQ undergoes hepatic metabolism and induces accumulation
of methemoglobin, generates reactive oxygen species (ROS) leading to oxidative stress and also
cause depletion of GSH in human erythrocytes (Ganesan et al. 2009; Ganesan et al. 2012). This
hypothesis is consistent with several other in vitro studies done with 5-HPQ and 6-methoxy-8hydroxylaminoquinoline (MHQ) in rat erythrocytes (Bolchoz et al. 2001; Bolchoz et al. 2002a;
Bowman et al. 2004; Bowman et al. 2005a). In G6PDd erythrocytes absence of G6PD enzyme
compromises the capacity to regenerate NADPH and recycle GSH. The G6PDd erythrocytes also
have compromised the ability for detoxification of ROS. Thus, three biomarkers, described above
are demonstrated as the potential biochemical markers for hemolytic response in human
erythrocytes.
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Figure 2.1: Metabolism of PQ to 5-hydroxy-primaquine (5-HPQ) through CYP2D6, and redox
cycling of 5-HPQ to its corresponding quinone imine and ortho-quinone. The figure is adapted
from (Marcsisin et al. 2016).
Recent reports have shown that the erythrocytes subjected to the hemolytic response due
to pathophysiological factors or external insults; undergo specific biochemical and cellular
changes. These changes have been collectively referred as eryptosis, which is similar to apoptosis
in nucleated eukaryotic cells (Lang et al. 2006; Lang et al. 2012). As erythrocytes do not contain
mitochondria and nucleus, they are devoid of the classical apoptotic pathways and apoptotic
characteristics such as mitochondrial depolarization and condensation of nuclei. The signaling
pathways, which lead to eryptosis, are different from classical pathways of apoptosis. However,
eryptosis shares some traits of apoptosis-like cell shrinkage, cell membrane blebbing, and exposure
of phosphatidylserine (PS) on the cell surface. Eryptosis could be induced by the agents that cause
oxidative stress (Lang et al. 2006; Lang et al. 2012). Exposure to PQ generates severe oxidative
stress in erythrocytes (Ganesan et al. 2009), which is presumably triggered by the PQ metabolites
produced through CYP-mediated pathways. In normal individuals’ presence of a G6PD, the
enzyme in pentose phosphate pathway, generate NADPH and formation of GSH is not
compromised and thus, oxidative stress has been taken care. Nevertheless, in G6PD deficiency,
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the capability of coping with oxidative stress is compromised (Judith Recht 2014). The events
involved in eryptosis, commit the damaged erythrocyte to be removed from the circulation through
extravascular mechanisms. The exposure of PS on the outer membrane is the ultimate commitment
of erythrocyte to be phagocytized by the macrophages (Lang et al. 2012).

2.2. HYPOTHESIS
Phenolic and quinone metabolites, generated through CYP-mediated pathways are
responsible for the hemolytic toxicity of PQ. These metabolites cause selective changes in early
and late biochemical markers of hemolytic toxicity in G6PDd erythrocytes as compared to normal
erythrocytes.

2.3. OBJECTIVE
The purpose of this study was to understand the mechanism of hemolytic toxicity of PQ
through evaluation of key biochemical parameters namely, the accumulation of methemoglobin
(MtHb), generation of oxidative stress and the levels of reduced glutathione (GSH). These
parameters were monitored in normal and G6PDd erythrocytes treated with PQ metabolites.
Changes in cellular markers associated with eryptosis were analyzed as late biomarkers of
hemotoxic response. The metabolites were tested for a dose-dependent hemolytic response.

2.4. MATERIALS AND METHODS.
2.4.1. Chemicals
2,7-Dichlorofluorescein diacetate (DCFDA), betulinic acid, D-(+)-glucose and tris(2carboxyethyl)phosphine hydrochloride (TCEP) were purchased from Sigma–Aldrich (St. Louis,
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MO, USA). GSH-Glo™ Glutathione Assay kit and Annexin V-FITC Apoptosis Detection kit were
purchased from Promega (Madison, WI, USA) and Abcam (Cambridge, MA, USA) respectively.
5-hydroxy-primaquine (5-HPQ), 5,6-orthoquinone-primaquine (5,6-OQPQ) and 6-methoxy-8hydroxylaminoquinoline (MAQ-NOH or MHQ) were synthesized by Dr. N.P. Dhammika.
Nanayakkara at the National Center for Natural Products Research (NCNPR), University of
Mississippi (Fasinu et al. 2014). The 5-HPQ is relatively unstable compound and undergo rapid
spontaneous oxidation. Time-lapse LC-MS analysis suggested the in the solution 5-HPQ instantly
converted to quinone-imine and 5,6-orthoquinone analog. Other reagents used were of highest
purity grade available.

2.4.2. Procurement of human blood
Blood was drawn from normal and glucose 6-phosphate dehydrogenase deficient (G6PDd)
healthy volunteers under an IRB approved protocol and stored at 4 0C. To analyze early biomarkers
of hemolytic response (MtHb formation, ROS generation, GSH and total glutathione estimation)
of 5-HPQ and 5,6-OQPQ, the G6PDd blood taken from an African American male carrying the
classic A/A- a combination of electrophoretic variant (Asn126Asp) and deficiency allele
(Val68Met) was used. To determine the hemolytic response of MHQ, G6PDd blood was obtained
a Caucasian male containing the Ser188Phe Mediterranean mutation was used. To evaluate
phosphatidylserine exposure, the late eryptosis response, induced by 5,6-OQPQ, G6PDd blood
taken from an African American male carrying the classic A/A- a combination of electrophoretic
variant (Asn126Asp) and deficiency allele (Val68Met) was used.
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2.4.3. Preparation of erythrocytes for hemotoxicity assays
The normal and G6PDd blood were centrifuged at 4500 g at 4 ◦C for 10 minutes, and buffy
coats were removed. The erythrocyte pellets were washed twice with chilled phosphate buffered
saline (110 mM sodium chloride, 20 mM disodium hydrogen phosphate and 4 mM potassium
dihydrogen phosphate, pH 7.4) with 10 mM glucose (PBSG). The washed erythrocytes pellets
were suspended at 50% hematocrit in chilled PBSG.

2.4.4. In vitro hemotoxic assays
The in vitro hemotoxic assays were adapted from an earlier in vitro metabolism-linked
hemotoxicity assay (Ganesan et al. 2012; Ganesan et al. 2009). In these assays, different
biochemical, molecular and cellular changes, which have been linked to oxidative hemotoxicity
were measured. The hemotoxic assays namely, the formation of methemoglobin, generation of
ROS, levels of intraerythrocytic GSH and total glutathione were measured as early hemotoxic
biomarkers. Externalization of PS on the outer membrane of erythrocytes was measured as a late
eryptotic biomarker. The PQ metabolites 5-HPQ, 5,6-OQPQ and MHQ were tested at the
concentrations ranging from 3.125 to 25 µM. The structures of PQ, 5-HPQ, 5,6-OQPQ and MHQ
are shown in Figure. 2.2
2.4.4.1. Methemoglobin formation assay
The reaction mixture contained 50 µl erythrocytes suspended in PBSG with 50%
hematocrit, 2.5 µl of test metabolite (5-HPQ, 5,6-OQPQ or MHQ) and PBSG to make a final
volume of reaction mixture to 200 µl. The reaction mixture with appropriate control without test
drug was also set up simultaneously. Each assay was set up at least in duplicates. The reaction
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mixtures were incubated for 1 hour at 370C in a shaking water bath. After incubation, samples
were kept on ice and methemoglobin levels were measured by a Co-Oximeter (IL-682).

Figure 2.2: Structure of primaquine (PQ) and its metabolites. 5-HPQ (5-hydroxy-primaquine), 5,
6-OQPQ (5, 6-orthoquinone of primaquine) and MHQ (6-methoxy-8-hydroxylaminoquinoline).
2.4.4.2. Reactive oxygen species (ROS) formation (oxidative stress kinetics assay)
This assay was performed in clear flat bottom 96 well plates. The washed normal and
G6PDd erythrocytes (50% hematocrit) were loaded with DCFDA, a fluorescent ROS probe. The
PBSG washed erythrocytes (50% hematocrit) were incubated with 600 µM DCFDA at 37 0C for
20 min and centrifuged at 4500 X g for 10 minutes. The DCFDA loaded erythrocytes pellet was
resuspended in PBSG to 50% hematocrit and used for the ROS formation assay. The reaction
mixtures contained 100 µL DCFDA loaded erythrocytes (50% hematocrit) and 2 µl test drug
(3.125 µM - 25 µM). Appropriate control without test drug was also set up at the same time. The
plate was read for 2 (every 5 minutes) hours at 370C on a fluorescence microplate reader for kinetic
measurement of fluorescence (excitation 488 nm and emission 535 nm). The data were recorded
as relative fluorescence units (RFU), and the time-dependent increase in fluorescence was
calculated in Excel software.
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2.4.4.3. Estimation of intraerythrocytic reduced glutathione (GSH) and total glutathione
levels.
The initial reaction set up for GSH, and total glutathione estimation assay was similar to
that for the methemoglobin formation assay described above. The estimation of GSH and total
glutathione was done with GSH-Glo™ Glutathione Assay Kit (Promega). To prepare the samples
for GSH and total glutathione a 5 µl aliquot was mixed with 20 µl GSH-Glo buffer and kept on
ice for at least 20 minutes. The samples were centrifuged at 10650 X g for 10 min at 4 0C. The
supernatants were transferred to separate tubes, and 225 µl of distilled water was added to the
supernatants. The samples were vortexed and used for intraerythrocytic GSH and total glutathione
determination. Aliquots of 2.5 µl from each sample were transferred to a fresh 96 wells microplate
and 25 ml GSH-Glo reagent was added to each well. The plate was incubated for 30 min at 25°C
on a shaker. Luciferin detection reagent (25 µl) was added to each well and plate was further
incubated for 15 min at room temperature on a shaker. Luminescence was read at 100 integrations
on a luminescence microplate reader. Aliquots (2.5 µl each) from the reaction mixtures were mixed
with 2.5 µl tris(2-carboxyethyl)phosphine hydrochloride (TCEP) (final concentration 500 µM) and
incubated with 25 µl GSH-Glo reagent for 30 min at 25°C on a shaker. TCEP was used to reduce
all glutathione into GSH (Winther and Thorpe 2014). The remaining experimental method was
similar to the GSH determination assay. Reduced glutathione at 6.25 µM was used as a standard.
The data was obtained as relative luminescence unit (RLU). To calculate GSH and total glutathione
in blood following formula was used. The concentration of GSH or total glutathione (µmoles/mL
blood)
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= (𝑅𝐿𝑈 𝑜𝑓 𝑐𝑜𝑟𝑟𝑒𝑠𝑝𝑜𝑛𝑑𝑖𝑛𝑔 𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 ∗ 25 ∗ 2.5 ∗ 50 ∗ 400 ∗ 5)/(RLU of standard X
1000 X 1000)

2.4.4.4. Evaluation of phosphatidylserine exposure (Annexin V binding assay).
The externalization of phosphatidylserine was evaluated by flow cytometric assays using
Annexin V-FITC Apoptosis Detection kit, Abcam. The annexin V shows high affinity for exposed
phosphatidylserine on the cell surface, and thus it is used as a probe to detect the
phosphatidylserine externalization. To prepare the samples, 50 µl of the washed normal and
G6PDd erythrocytes (suspended in PBSG with 50% hematocrit) were treated with 2.5 µl
metabolite. PBSG was added to make a final volume of reaction mixture to 250 µl. Samples were
incubated for 24 hours at 37 0C in a shaking water bath. After incubation, the aliquots containing
1×106 erythrocytes were removed and centrifuged at 4500 X g for 10 min at 4 0C. The supernatants
were removed. The erythrocytes’ pellets were resuspended in 500 µL of binding assay buffer and
5 µL Annexin-FITC binding dye was added. The reaction mixtures were incubated for 5 minutes
at room temperature in the dark. Annexin V-FITC binding was analyzed by flow cytometry
(excitation = 488 nm; emission = 530 nm) using FITC signal detector (FL1). Data were recorded
for 10,000 events per sample. Betulinic acid (10 µM) was used as a positive control in this assay.
Betulinic acid, a pentacyclic lupane-type triterpene derivative of botulin, is isolated from the bark
of Betula pubescens. Treatment of human erythrocytes in vitro treatment with betulinic acid
induces eryptosis via membrane permeabilization and phosphatidylserine externalization
(Macczak et al. 2016). The data was obtained as mean fluorescence and mean fluorescence of M2
population was used for analysis.
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2.4.5. Statistical analysis.
Multiple comparisons among groups mean were analyzed by two-way ANOVA followed
by Tukey’s post hoc tests using GraphPad Prism® version 7.3. The p values <0.05 were considered
as significant difference. Data are presented as a mean ± standard error (SE).

2.5. RESULTS
2.5.1. Methemoglobin formation
The washed normal and G6PDd human erythrocytes were incubated with the test
compounds at 37 0C for an hour and then analyzed with Co-oximeter to determine methemoglobin.
Exposure of erythrocytes to oxidative reactions converts the Fe +2 oxyhemoglobin to Fe+3
methemoglobin, which loses the oxygen carrying capacity. The increase in blood methemoglobin
levels, referred as methemoglobinemia, is an important diagnostic marker for oxidative stress.
Treatment of human erythrocytes with 5-HPQ, 5,6-OQPQ, and MHQ in vitro caused a robust and
concentration-dependent increase in methemoglobin formation in normal and G6PDd human
erythrocytes (Figure 2.3). Treatment with 5-HPQ produced a significant increase in
methemoglobin levels in normal erythrocytes at 12.5 and 25 µM (p< 0.001 and p< 0.001
respectively), as compared to vehicle control. Similarly, 5-HPQ treatment significantly increased
methemoglobin in G6PDd erythrocytes at 6.25, 12.5 and 25 µM (p< 0.05, p< 0.0001 and p< 0.0001
respectively) as compared to vehicle control. The increase in methemoglobin level due to 5-HPQ
treatment was almost similar in normal and G6PDd human erythrocytes at all the concentration
levels tested, except at 25 µM, which caused a statistically significant increase in methemoglobin
in G6PDd erythrocytes compared to normal (p< 0.01) (Figure 2.3.A).
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Similarly, 5,6-OQPQ treatment also produced concentration-dependent increase in
methemoglobin level, which was statistically significant at the concentration levels tested at 6.25,
12.5 and 25 µM as compared to the vehicle control, both in normal (p< 0.001, p< 0.0001 and p<
0.0001 respectively) and G6PDd (p< 0.0001, p< 0.0001 and p< 0.0001 respectively) human
erythrocytes (Figure 2.3.B). Again, the increase in methemoglobin level due to 5,6-OQPQ
treatment was almost similar in normal and G6PDd human erythrocytes at all the concentration
levels tested.
The des-alkylated PQ metabolite MHQ, also produced significant increase in
methemoglobin at 6.25, 12.5 and 25 µM, MHQ, as compared to vehicle control, both in normal
(p< 0.001, p< 0.0001 and p< 0.0001 respectively) and G6PDd (p< 0.01, p< 0.0001 and p< 0.0001
respectively) human erythrocytes (figure 2.3.C). The methemoglobin formation induced by MHQ
was statistically not different in normal and G6PD deficient erythrocytes. However, at the highest
concentration, methemoglobin formation induced by MHQ was significantly lower compared to
that induced due to the treatment with 5-HPQ and 5,6-OQPQ, both in normal (p< 0.01 and p<
0.0001 respectively) and G6PDd erythrocytes (p< 0.0001 and p< 0.0001 respectively).
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Figure 2.3: Methemoglobin formation in normal and G6PDd human erythrocytes due to treatment
with (A) 5-HPQ, (B) 5,6-OQPQ and (C) MHQ. Each data point represents mean ± SE of at least
duplicate observations. The results were statistically analyzed with GraphPad Prism® with twoway ANOVA followed by Tukey’s multiple comparison test and P values <0.05 were considered
as statistically significant. **p < 0.01 compared with G6PDd erythrocyte with corresponding
concentration.
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2.5.2. Generation of reactive oxygen species (ROS)
To determine the effect of 5-HPQ, 5,6-OQPQ and MHQ on oxidative stress, the reactive
oxygen species (ROS) generation in both normal and G6PDd human erythrocytes was measured
using the fluorescent dye, DCFDA. Like methemoglobin toxicity, all the three metabolites namely,
5-HPQ, 5,6-OQPQ and MHQ generated significant, concentration-dependent ROS in normal and
G6PDd human erythrocytes, which is indicated by an increase in fluorescence. Generation of
oxidative stress (increase in ROS) due to 5-HPQ exposure was statistically significantl at all the
concentrations (3.125 to 25 µM) tested (p< 0.0001), in normal human erythrocytes. In G6PDd
human erythrocytes, 5-HPQ exposure caused significant increase in oxidative stress at 6.25, 12.5
and 25 µM as compared to vehicle control (p< 0.01, p< 0.0001 and p< 0.0001, respectively)
(Figure 2.4). ROS formation caused by 5-HPQ was significantly higher at 3.125, 6.25 and 12.5
µM concentration (p< 0.05, p< 0.01 and p< 0.001, respectively) in normal versus G6PDd
erythrocytes (Figure 2.4).
Similar to 5-HPQ, 5,6-OQPQ also generated robust ROS in normal human erythrocytes
3.125, 6.25, 12.5 and 25 µM as compared to vehicle control (0 µM) in normal (p< 0.05, p< 0.01,
p< 0.0001 and p< 0.0001, respectively). However, in G6PDd human erythrocytes, exposure of 5,6OQPQ produced significant ROS at 12.5 and 25 µM concentration (p< 0.001 and p< 0.0001,
respectively) (Figure 2.5). 5,6-OQPQ produced considerably higher ROS in normal erythrocytes
(p< 0.01) as compared to G6PDd human erythrocytes only at 25 µM (Figure 2.5). Generation of
oxidative stress (increase in ROS) due to MHQ exposure was statistically significant at all the
concentrations (3.125 to 25 µM) tested (p< 0.0001), both in normal and G6PDd human
erythrocytes (Figure 2.6). However, ROS formation caused by MHQ was not significantly
different in normal versus G6PDd erythrocytes (Figure 2.6).
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Thus, these data suggest that 5-HPQ, 5,6-OQPQ, and MHQ generated considerable
oxidative stress in normal and G6PDd human erythrocytes. MHQ did not produce significantly
different oxidative stress in normal as compare to G6PDd human erythrocytes. However, 5-HPQ
and 5,6-OQPQ produced statistically higher amount of oxidative stress in normal as compare to
G6PDd human erythrocytes (Figure 2.4, 2.5 and 2.6).
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Figure 2.4: Generation of reactive oxygen species, shown by increase in fluorescence in
DCFDA loaded normal and G6PDd human erythrocytes by 5-HPQ exposure. (A) RFU at 120
minutes in normal and G6PDd human erythrocytes exposed to 5-HPQ. Each data point
represents mean ± SE of at least duplicate observations. The results were analyzed with
GraphPad Prism® with two-way ANOVA followed by Tukey’s multiple comparison test and P
values <0.05 were considered as statistically significant. Time-dependent increase in
fluorescence due to reactive oxygen species generation in (B) normal, and (C) G6PDd human
erythrocytes exposed to different concentration of 5-HPQ. Each data point is mean of at least
duplicate observations. RFU- Relative fluorescence unit.
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Figure 2.5: Generation of reactive oxygen species, shown by increase in fluorescence in DCFDA
loaded normal and G6PDd human erythrocytes by 5,6-OQPQ exposure. (A) RFU at 120 minutes
in normal and G6PDd human erythrocytes exposed to 5-HPQ. Each data point represents mean ±
SE of at least duplicate observations. The results were analyzed with GraphPad Prism® with twoway ANOVA followed by Tukey’s multiple comparison test and P values <0.05 were considered
as statistically significant. Time-dependent increase in fluorescence due to reactive oxygen species
generation in (B) normal, and (C) G6PDd human erythrocytes exposed to different concentration
of 5,6-OQPQ. Each data point is mean of at least duplicate observations. RFU- Relative
fluorescence unit.
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Figure 2.6: Generation of reactive oxygen species, shown by increase in fluorescence in DCFDA
loaded normal and G6PDd human erythrocytes by MHQ exposure. (A) RFU at 120 minutes in
normal and G6PDd human erythrocytes exposed to 5-HPQ. Each data point represents mean ± SE
of at least duplicate observations. The results were analyzed with GraphPad Prism® with two-way
ANOVA followed by Tukey’s multiple comparison test and P values <0.05 were considered as
statistically significant. Time-dependent increase in fluorescence due to reactive oxygen species
generation in (B) normal, and (C) G6PDd human erythrocytes exposed to different concentration
of MHQ. Each data point is mean of at least duplicate observations. RFU- Relative fluorescence
unit.
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2.5.3. Estimation of intraerythrocytic reduced glutathione (GSH) levels.

To estimate the effect of 5-HPQ, 5,6-OQPQ and MHQ on the intraerythrocytic GSH level
in normal and G6PDd human erythrocytes enzymatic luciferase assay was used. The basal GSH
level (vehicle control, 0 µM) in G6PDd human erythrocytes was significantly lower as compared
to normal human erythrocytes (p<0.001) (Figure. 2.7.A and 2.7.C) suggesting that the depletion
in GSH level in G6PDd erythrocytes is because of the genetic defect. Treatment of 5-HPQ
increased GSH at 3.125 µM (5.6 %) and decreased GSH at 12.5 µM and 25 µM (5.7% and 10.7%
respectively) relative to vehicle control in normal human erythrocytes (Figure. 2.7.B). However,
the increase and decrease in GSH level due to treatment in normal erythrocytes was not significant.
Treatment of 5-HPQ caused concentration-dependent depletion in GSH level at 3.125 µM, 6.25
µM (40.9%), 12.5 µM (46.8%) and 25 µM (74.7%) in G6PDd human erythrocytes as compared to
vehicle control and the depletion in GSH levels were not significant (Figure. 2.7.A and 2.7.B).
Exposure of 5,6-OQPQ, increased GSH at 3.125 µM (5.5%), 6.25 µM (8.4%), 12.5 µM
(6.04 %) relative to untreated normal human erythrocytes (Figure. 2.7.D). The increased in GSH
level due to treatment in normal erythrocytes was not significant. Exposure of 5,6-OQPQ caused
concentration-dependent depletion in GSH level at 3.125 µM (41.7%), 6.25 µM (61%; p< 0.05),
12.5 µM (77.8%; p< 0.01) and 25 µM (85.1%; p< 0.01) in G6PDd human erythrocytes as compare
to vehicle control (Figure. 2.7.C and 2.7.D).
MHQ caused, increase in GSH levels at 3.125 µM (62.1%), 6.25 µM (40.6%), 12.5 µM
(24.4%) and 25 µM (0.33%) relative to vehicle control in normal human erythrocytes (Figure.
2.7.F). In G6PDd erythrocytes, MHQ increased GSH levels at 3.125 µM (18.7%), 12.5 µM (16%)
and 25 µM (21.6%) and depleted GSH levels at 3.125 µM (14,3%) relative to vehicle control in
G6PDd human erythrocytes (Figure. 2.7.F). The effect of MHQ in GSH levels in normal and
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G6PDd human erythrocytes was not significant (Figure. 2.7.E). Thus, these results indicate that
5,6-OQPQ caused concentration-dependent depletion in GSH level selectively in G6PDd human
erythrocytes.
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Figure 2.7: Intraerythrocytic GSH levels of normal and G6PDd human erythrocytes treated with
(A) 5-HPQ, (C) 5,6-OQPQ and (E) MHQ. Each data point represents mean ± SE of at least
duplicate observations. The results were analyzed with GraphPad Prism® with two-way ANOVA
followed by Tukey’s multiple comparison test and P values <0.05 were considered as statistically
significant. *p < 0.05, ***p < 0.001 and ****p < 0.0001 compared with normal erythrocyte with
corresponding concentration. Percent change in intraerythrocytic GSH levels of normal and
G6PDd human erythrocytes due to treatment with (B) 5-HPQ, (D) 5,6-OQPQ and (F) MHQ. The
percent change in intraerythrocytic GSH levels in treated normal and treated G6PDd erythrocytes
are expressed relative to those in vehicle control in normal and G6PDd erythrocytes respectively.
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2.5.4. Estimation of intraerythrocytic total glutathione levels.
Total intraerythrocytic glutathione level was also measured by enzymatic luciferase assay
using TCEP as reducing agent to thiol (Winther and Thorpe 2014). The results suggest that the
basal total intraerythrocytic glutathione levels (vehicle control) were lower in G6PDd human
erythrocytes as compared to normal human erythrocytes. However, the difference was not
statistically significant (54.7% in Figure 2.8.A, 37.3% in Figure 2.8.C and 34.9% in Figure 2.8.E).
Exposure of 5-HPQ increased total glutathione levels at 3.125 µM (4.6%) and decreased total
glutathione levels at 6.25 µM (2.8%),12.5 µM (6.9%) and 25 µM (15%) relative to vehicle control
in normal human erythrocytes (Figure. 2.8.B). Treatment of 5-HPQ caused an increase in total
glutathione levels at 3.125 (67%), 6.25 (5.1%), 12.5 (42.7%) and 25 µM (10.8%) in G6PDd human
erythrocytes as compare to vehicle control (Figure 2.8.B). However, the effect of 5-HPQ on total
glutathione levels was not significant at any concentration (3.125-25 µM) as compared to vehicle
control in normal and G6PDd erythrocytes (Figure 2.8.A and 2.8.B).
Treatment of 5,6-OQPQ, increased total glutathione levels at 3.125 µM (8.1%), 6.25 µM
(6.3%) and 25 µM (2.7%) and decreased total glutathione levels at 12.5 µM (1.9%) relative to
vehicle control in normal human erythrocytes (Figure. 2.8.D). 5,6-OQPQ caused decrease in total
glutathione levels at 3.125 (13.9%), 6.25 (18.9%), 12.5 (7.4%) and 25 µM (7.4%) in G6PDd
human erythrocytes as compare to vehicle control (figure. 2.8.D). However, 5,6-OQPQ did not
have any significant effect on total glutathione levels at any concentration (3.125-25 µM) as
compared to vehicle control in normal and G6PDd erythrocytes (Figure. 2.8.C and 2.8.D).
MHQ caused an increase in total glutathione levels at 3.125 (69.8%), 6.25 (58.3%), 12.5
µM (54.9%) and decreased at 25 µM (3.55%) relative to vehicle control in normal human
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erythrocytes (Figure 2.8.F). In G6PDd erythrocytes, MHQ increased total glutathione levels at
3.125 (45,2%), 6.25 (3.9%), 12.5 (37.5) and 25 µM (62.5%) relative to vehicle control in G6PDd
human erythrocytes (Figure 2.8.F). Though, the effect of MHQ on total glutathione levels in
normal and G6PDd human erythrocytes was not significant as compared to vehicle control (Figure
2.8.E). These results indicate that 5-HPQ, 5,6-OQPQ, and MHQ did not cause significant effect
on total glutathione level in normal and G6PDd human erythrocytes.
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Figure 2.8: Intraerythrocytic total glutathione levels of normal and G6PDd human erythrocytes
treated with (A) 5-HPQ, (C) 5,6-OQPQ and (E) MHQ. Each data point represents mean ± SE of
at least duplicate observations. The results were analyzed with GraphPad Prism® with two-way
ANOVA followed by Tukey’s multiple comparison test and P values <0.05 were considered as
statistically significant. *p < 0.05 compared with normal erythrocyte with corresponding
concentration. Percent change in intraerythrocytic total glutathione levels of normal and G6PDd
human erythrocytes due to treatment with (B) 5-HPQ, (D) 5,6-OQPQ and (F) MHQ. The percent
change in intraerythrocytic GSH levels in treated normal and treated G6PDd erythrocytes are
expressed relative to those in vehicle control in normal and G6PDd erythrocytes respectively.
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2.5.5. Determination of phosphatidylserine exposure in human erythrocytes.
The flow cytometric assay employing FITC Annexin V binding assay was used to
determine phosphatidylserine externalization in normal and G6PDd erythrocytes. Betulinic acid
was tested as a positive control in this assay. Translocation of phosphatidylserine on the outer
membrane of erythrocytes due to treatment with 5,6-OQPQ (25 µM) and a comparative evaluation
of translocation of phosphatidylserine in normal and G6PDd erythrocytes due to 5,6-OQPQ
exposure was done. Treatment with betulinic acid caused a significant increase in
phosphatidylserine exposure both in normal (p<0.01) and G6PDd erythrocytes (p<0.001).
Treatment with betulinic acid caused statistically more externalization of phosphatidylserine in
G6PDd erythrocytes versus normal erythrocytes (p<0.05). Treatment with 5,6-OQPQ induced
phosphatidylserine externalization in both normal and G6PDd erythrocytes, however, the increase
in phosphatidylserine externalization was statistically significant (p<0.01) only in G6PDd
erythrocytes. Treatment with 5,6-OQPQ induced significantly higher phosphatidylserine
externalization in G6PDd as compared to normal erythrocytes (p<0.01) (Figure 2.9). Thus, these
results suggest that 5,6-OQPQ caused externalization of phosphatidylserine on the outer surface
of G6PDd human erythrocytes.
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Figure 2.9: Phosphatidyl serine exposure (as analyzed by Annexin V binding) induced by 5,6OQPQ in normal and G6PDd human erythrocytes. Each data point represents mean ± SE of at
least duplicate observations. The results were analyzed with GraphPad Prism® with two-way
ANOVA followed by Tukey’s multiple comparison test and P values <0.05 were considered as
statistically significant. **p < 0.01, ***p < 0.01 compared with corresponding erythrocyte and
vehicle control. ap < 0.05, bp < 0.01 compared with normal human erythrocytes exposed with
corresponding treatment.
2.5.6. Comparative hemolytic response of 5-HPQ, 5,6-OQPQ, and MHQ
The methemoglobin formation induced by 5-HPQ, 5,6-OQPQ and MHQ was compared at
the highest concentration (25 µM) used in the assay. The results suggest that methemoglobin
formation caused by 5,6-OQPQ was significantly higher as compared to that of caused due to 5HPQ and MHQ in normal (p< 0.001 and p< 0.0001 respectively). However, in G6PDd
erythrocytes, 5,6-OQPQ induced methemoglobin formation was significantly higher as compared
to MHQ (p< 0.0001) and 5-HPQ (p> 0.05). Similarly, 5-HPQ formed significantly higher
methemoglobin as compared to MHQ in normal and G6PDd erythrocytes (p< 0.01 and p< 0.0001
respectively). Thus, these results suggest PQ metabolites formed methemoglobin in the following
order: 5,6-OQPQ > 5-HPQ > MHQ in normal and G6PDd erythrocytes (Figure 2.3).
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Similarly, oxidative stress generated by 5-HPQ, 5,6-OQPQ and MHQ was compared at the
highest concentration (25 µM) used in the assay. The comparison suggests that ROS generation
induced by MHQ was significantly higher as compared to that of induced by 5-HPQ (p< 0.0001)
and 5,6-OQPQ (p< 0.0001) in normal and G6PDd erythrocytes. However, 5-HPQ did not generate
significantly different ROS as compared to 5,6-OQPQ in normal and G6PDd erythrocytes (Figure
2.4, 2.5 and 2.6). Thus, these results suggest PQ metabolites generates oxidative stress in following
order: MHQ > 5-HPQ = 5,6-OQPQ in normal and G6PDd erythrocytes.
The depletion in GSH levels caused by 5-HPQ, 5,6-OQPQ, and MHQ was also compared
at the highest concentration (25 µM) used in the assay in G6PDd erythrocytes only since
metabolites did not have any significant depletion in normal erythrocytes. Treatment of 5-HPQ
and 5,6-OQPQ caused depletion (74.7% and 85.1%; p< 0.01 respectively) in GSH levels in G6PDd
human erythrocytes as compare to vehicle control. However, MHQ caused 18.7% increase in
G6PDd erythrocytes. However, the GSH depletion caused by 5,6-OQPQ was significant.

2.6. DISCUSSION
PQ treatment to G6PD individuals causes severe hemolysis accompanied with dark urine
and mild jaundice (Ashley et al. 2014; Clayman et al. 1952; Hockwald et al. 1952). The clinical
manifestations of hemolytic toxicity depend mainly on the dose of PQ and severity of the patient’s
G6PD genetic defect (Ashley et al. 2014; Cappellini and Fiorelli 2008). Various groups studied
both in vitro and in vivo hemotoxic effects of PQ (Hong et al. 1992; Vasquez-Vivar and Augusto
1992, 1994; Morais Mda and Augusto 1993; Bolchoz et al. 2001; Bolchoz et al. 2002b; Bolchoz
et al. 2002a; Bowman et al. 2004; Bowman et al. 2005b; Bowman et al. 2005a; Ganesan et al.
2009; Ganesan et al. 2012; Garg et al. 2011). The efficacy and hemolytic toxicity of PQ depend
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on hepatic metabolism (Ganesan et al. 2009; Ganesan et al. 2012; Xuan et al. 2016). Although
numerous studies have been done in last two decades, to understand the underlying mechanism of
PQ-induced hemolysis still, the metabolite (s) and pathway (s), which are responsible for the
hemolytic toxicity is not clear and inadequate.
Ganesan et al. analyzed the hemotoxic effect of PQ in the presence of human liver
microsomes (HLM), mouse liver microsomes (MLM) and recombinant human-CYPs isoforms in
normal and Glucose-6-Phosphate Dehydrogenase-deficient (G6PDd) human erythrocytes
(Ganesan et al. 2009; Ganesan et al. 2012). The studies showed that in the presence of HLM, PQinduced methemoglobin (MtHb) formation, reactive oxygen species (ROS) generation, and
depletion in thiols in human erythrocytes (Ganesan et al. 2009; Ganesan et al. 2012). Multiple
CYP isoforms (CYP2E1, CYP2B6, CYP1A2, CYP2D6, and CYP3A4) were found to mediate the
metabolism of PQ and cause PQ-associated hemotoxicity in human erythrocytes (Ganesan et al.
2009). Recent studies revealed that the production of 5-HPQ and other phenolic metabolites of PQ
depend on of CYP2D6-mediated metabolism (Fasinu et al. 2014; Pybus et al. 2012; Pybus et al.
2013; Potter et al. 2015).
The current studies mentioned in this chapter suggest that 5-HPQ and MHQ are hemotoxic
metabolites of PQ. 5-HPQ and MHQ produced a robust generation of methemoglobin and
oxidative stress in normal and G6PDd human erythrocytes. 5-HPQ caused depletion of GSH
selectively in G6PDd human erythrocytes. However, MHQ did not cause depletion in GSH levels
in either human erythrocytes. The results found in our studies regarding 5-HPQ and MHQ
hemotoxicity are consistent with previous studies done on 5-HPQ and MHQ on rat erythrocytes
(Bolchoz et al. 2001; Bolchoz et al. 2002b; Bolchoz et al. 2002a; Bowman et al. 2004; Bowman
et al. 2005b; Bowman et al. 2005a). These studies suggested that 5-HPQ caused methemoglobin
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formation, depletion of GSH (Bowman et al. 2004) and generation of ROS in rat erythrocytes
(Bowman et al. 2005b), and MHQ resulted in oxidation of GSH (Bolchoz, Morrow et al. 2002),
and generated oxidative stress (Bolchoz, Gelasco et al. 2002) in rat erythrocytes (Bolchoz,
Budinsky et al. 2001, Bolchoz, Gelasco et al. 2002, Bolchoz, Morrow et al. 2002). Although, our
result did not show the effect of MHQ on GSH depletion/oxidation since the concentration of
MHQ used by Bolchoz et al. was 350 µM. Our studies also explored the hemotoxic mechanism of
5,6-OQPQ, the spontaneously transformed product of 5-HPQ, which has been identified only
recently (Fasinu et al. 2014). The results showed that 5,6-OQPQ caused concentration-dependent
generation of methemoglobin and oxidative stress in normal and G6PDd human erythrocytes and
also induced concentration-dependent depletion of GSH selectively in G6PDd human
erythrocytes. The comparative hemolytic response of 5-HPQ, 5,6-OQPQ, and MHQ suggest that
5,6-OQPQ formed the highest amount of methemoglobin, followed by 5-HPQ and MHQ in normal
and G6PDd erythrocytes. MHQ generated highest oxidative stress as compared to 5-HPQ and 5,6OQPQ in normal and G6PDd erythrocytes. 5-HPQ and 5,6-OQPQ generated the almost similar
amount of oxidative stress in normal and G6PDd erythrocytes. Furthermore, 5,6-OQPQ caused
higher GSH depletion followed by 5-HPQ and MHQ in G6PDd erythrocytes.
5,6-OQPQ caused externalization of phosphatidylserine on the outer surface of G6PDd
human erythrocytes suggesting the involvement of eryptosis in PQ-induced hemotoxicity.
However, previous studies showed that eryptosis might not be involved in removing damaged
erythrocytes, which occur due to PQ hemotoxicity (Ganesan et al. 2012). However, in this study
(Ganesan et al. 2012), the erythrocytes were incubated with PQ alone in the presence of human
liver microsomes only for 3 hours. The short exposure time of 3 hours may not be sufficient to
61

trigger cellular changes in erythrocytes. Unlike current studies, where erythrocytes were incubated
with 5,6-OQPQ for 24 hours.
In conclusion, the current in vitro studies described here infers that 5-HPQ, 5,6-OQPQ, and
MHQ are hemotoxic metabolites of PQ and cause a concentration-dependent hemotoxic response
by forming methemoglobin, generating oxidative stress in normal and G6PDd human erythrocytes.
5,6-OQPQ depleted GSH and caused externalization of phosphatidylserine selectively in G6PDd
human erythrocytes. Exposure of PS on the outer membrane is the ultimate commitment of
erythrocyte to be phagocytized by macrophages. Thus, these results suggest that eryptotic pathway
triggers the removal of damaged erythrocytes from the circulation in the G6PDd population on
exposure to PQ.
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CHAPTER 3
THE ROLE OF NRH-QUINONE OXIDOREDUCTASE 2 IN HEMOLYTIC TOXICITY
OF PRIMAQUINE METABOLITES.

3.1. INTRODUCTION & RATIONALE
NRH-quinone oxidoreductase 2 (NQO2) is a cytosolic and ubiquitously expressed FADlinked oxidoreductive enzyme, catalyzes mandatory two-electron reductions of quinone to
hydroquinones without accumulating semiquinones and free radicals (Foster et al. 2000; Vella et
al. 2005). Thus, NQO2 seems to be the detoxification enzyme for quinones (Graves et al. 2002).
However, earlier reports suggest that NQO2 is also capable of causing metabolic activation of
quinones (Ferry et al. 2010). In addition, to reduction of quinone, NQO2 stabilizes the p53 tumor
suppressor (Khutornenko et al. 2010). NOQ2 gene is expressed in heart, liver, kidney, brain and
erythrocytes. Furthermore, only NQO2 is present in human erythrocytes and NADPH-quinone
oxidoreductase 1 (NQO1) is absent (Graves et al. 2002).
Human erythrocytic NQO2 is the only potential protein target identified for PQ (Ki1.04±0.38 µM) (Graves et al. 2002). Previous kinetics studies demonstrated that PQ preferentially
binds to the oxidized state of NQO2. PQ shows competitive inhibition against the electron donating
co-factor dihydronicotinamide riboside (NRH), and reduces FAD to FADH 2 (Leung and Shilton
2013). Ping-pong mechanisms can explain the inhibition of NQO2 by PQ and reduction
mechanism of NQO2. According to this mechanism, NQO2 protein has a unique catalytic site for
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the substrate and co-substrate. First, the co-substrate (an electron donor) occupies the site, releases
and converts the FAD to FADH2. After that, the substrate (an electron acceptor) enters the catalytic
site and is reduced (Leung and Shilton 2013; Vella et al. 2005; Kwiek et al. 2004).
NQO2 belongs to thioredoxin family of enzymes and is distinctive as it uses
dihydronicotinamide riboside (NRH) as a reducing coenzyme instead of NADH or NADPH.
Nicotinamide riboside, the oxidized form of the NRH, participates in NAD metabolism, although
the cellular source of the NRH, is still not known, and it is unclear why NQO2 uses NRH (Leung
and Shilton 2013; Long and Jaiswal 2000). Melatonin (Mel) (IC 50 = 41.5±1.5µM), resveratrol
(Res) (IC50 = 0.143±0.05 µM) and quercetin (Quer) (IC 50 = 1.4±0.1 µM) are potent inhibitors of
NQO2 (Figure 3.1) (Ferry et al. 2010; Boutin et al. 2005). As mentioned earlier, that NQO2 is the
only target identified for PQ and redox cycling of quinone and quinone-imine metabolites has been
implicated in hemotoxicity of PQ (Marcsisin et al. 2016). It is also known that in erythrocytes only
NOQ2 is present and NQO1 is absent, and NQO2 participates in quinone activation/detoxification
(Graves et al. 2002; Foster et al. 2000; Vella et al. 2005; Ferry et al. 2010). It seems NQO2 might
have a role in PQ-induced hemolytic toxicity. Thus, in the current study, Mel, Res and Quer, the
inhibitors of NQO2 were used as probes to investigate the function of NQO2 in PQ metabolitesinduced hemolytic toxicity.
Docking studies are a powerful tool to gain an understanding of interactions between the
protein and ligands (Grinter and Zou 2014; Huang and Zou 2010). With docking studies, the
binding mode and binding affinity between protein and ligand are determined and is important to
understand the overall mechanism and function of the protein-ligand complex (Huang and Zou
2010). Thus, the molecular docking between human NQO2 protein crystal structure (PDB id 4FGJ)
and metabolites of PQ was performed using Schrödinger software suite.
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Figure 3.1: Structures of NQO2 inhibitors.
3.2. HYPOTHESIS
The oxidative phenolic and quinone metabolites of PQ interact with NQO2, which
modulates redox cycling of PQ metabolites and their potential to cause hemolytic toxicity.

3.3. OBJECTIVE
The purpose of this study was to investigate the function of NQO2, a cytosolic flavoprotein
enzyme involved in metabolic detoxification/activation of quinones, in PQ-induced hemolytic
anemia. In this study, the hemolytic toxicity of PQ metabolites was evaluated in the presence of
NQO2 inhibitors, namely melatonin (Mel), resveratrol (Res) and quercetin (Quer) on normal and
G6PDd human erythrocytes. Further, the interactions between human NQO2 protein crystal
structure (PBD: 4FGJ) and metabolites of PQ were analyzed using computational docking
approach.

3.4. MATERIALS AND METHODS.
3.4.1. Chemicals

65

Melatonin, resveratrol, and quercetin were purchased from Sigma–Aldrich (St. Louis, MO,
USA). The information of remaining chemicals and kits were given in Chapter 2.

3.4.2. Procurement of human blood
Blood was drawn from normal and glucose 6-phosphate dehydrogenase deficient (G6PDd)
healthy volunteers under an IRB approved protocol and stored at 4 0C. To analyze the effect of
NQO2 inhibitors in early biomarkers of hemolytic response (MtHb formation, ROS generation,
GSH and total glutathione estimation) of 5-HPQ and 5,6-OQPQ, the G6PDd blood taken from an
African American male carrying the classic A/A- a combination of electrophoretic variant
(Asn126Asp) and deficiency allele (Val68Met) was used. To determine the effect of NQO2
inhibitors in the hemolytic response of MHQ, G6PDd blood was obtained a Caucasian male
containing the Ser188Phe Mediterranean mutation was used. To evaluate the effect of quercetin
on phosphatidylserine exposure, the late eryptosis response, induced by 5,6-OQPQ, G6PDd blood
taken from an African American male carrying the classic A/A- a combination of electrophoretic
variant (Asn126Asp) and deficiency allele (Val68Met) was used.

3.4.3. Preparation of erythrocytes for hemotoxicity assays
Similar to chapter 2 section 2.4.3

3.4.4. In vitro hemotoxic assays
The in vitro hemotoxic assays were similar to mentioned in chapter 2 section 2.4.4. The
concentration of NOQ2 inhibitors (melatonin, resveratrol, and quercetin) used was 100 µM.
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3.4.4.1. Methemoglobin formation assay
The reaction mixture contained 50 µl erythrocytes suspended in PBSG with 50%
hematocrit, 2.5 µl of test NQO2 inhibitor (Mel, Res, and Quer), 2.5 µl of test metabolite (5-HPQ,
5,6-OQPQ or MHQ) and PBSG to make a final volume of reaction mixture to 250 µl. Remaining
method is similar to “methemoglobin formation assay” mentioned in chapter 2 section 2.4.4.1.

3.4.4.2. Reactive oxygen species (ROS) formation (oxidative stress kinetics assay)
The reaction mixtures contained 100 µL DCFDA loaded erythrocytes (50% hematocrit), 2
µl test NQO2 inhibitor, 2 µl test metabolite and PBSG to make a final volume of reaction mixture
to 200 µl. The test NOQ2 inhibitor was first incubated with erythrocytes for 10 minutes at 37 0C
and then the test metabolite was added. Remaining method is similar to “ROS formation assay”
mentioned in chapter 2 section 2.4.4.2.

3.4.4.3. Estimation of intraerythrocytic reduced glutathione (GSH) and total glutathione
levels
The method is similar to “estimation of intraerythrocytic reduced glutathione (GSH) and
total glutathione levels” mentioned in chapter 2 section 2.4.4.3.

3.4.4.4. Evaluation of phosphatidylserine exposure (Annexin V binding assay)
To prepare the samples, 50 µl the washed normal and G6PDd erythrocytes (suspended in
PBSG with 50% hematocrit) were treated with 2.5 µl test NQO2 inhibitor and 2.5 µl test
metabolite. PBSG was added to make a final volume of reaction mixture to 250 µl. The test NOQ2
inhibitor was first incubated with erythrocytes for 10 minutes at 37 0C and then the test metabolite
67

was added. Samples were incubated for 24 hours at 37 0C in a shaking water bath. The method
was similar to “evaluation of phosphatidylserine exposure (Annexin V binding assay)” mentioned
in chapter 2 section 2.4.4.4.

3.4.5. Computational methods
The crystal structure of human NQO2 enzyme was downloaded from the protein data bank
[PDB ID: 4FGJ] (Leung and Shilton 2013). Protein structure was preprocessed for adding missing
hydrogens, adjusting bond orders, proper ionization, and refined using protein preparation wizard
in Schrödinger software suite v2016-1 (Schrödinger 2016a). We kept water molecules in the
crystal structure near 5Å of ligand binding site. There was no missing side chain; however,
alternate positions were found for few residues [MET116 (chain A), GLU153 (chain A), SER164
(chain A), MET116 (chain B), SER134 (chain B)] including PQ. We used the highest average
occupancy position of these residues as well as for PQ. The PROPKA program was used to predict
the protonation states for protein residues at pH 7.0. Finally, a restrained minimization considering
hydrogens only was performed using OPLS3 (Optimized Potentials for Liquid Simulations) force
field. All the ligands, PQ, PQ metabolites (5-HPQ, 5,6-OQPQ, and MHQ), menadione and
melatonin (Mel) were sketched using Maestro, and ionizable compounds were converted to their
most probable charged forms at physiological pH 7.4 and energy minimized using LigPrep module
implemented in the Schrödinger software (Sastry et al. 2013; Schrödinger 2016b). Furthermore,
the grid was prepared considering co-crystal ligand (primaquine) as the centroid of the active site
in the NQO2 protein. A scaling factor of 1.0 was applied to the van der Waals radii and docking
study was performed using Glide software considering extra precision (XP) docking method
(Friesner et al. 2006). The protein was kept rigid while ligands were flexible during docking. 5
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poses for each ligand were kept. Default settings were used for all remaining parameters if not
reported elsewhere. The best poses were ranked based on Emodel scores [a mathematical
combination of the Glide-score, the ligand strain (Einternal), and the Coulomb and van der Waals
energies]. Further binding free energy (Prime MM-GBSA) of the best protein-ligand complexes
was calculated using Prime module of the Schrödinger software. The docking score and interaction
profile between protein and ligands were further analyzed (Friesner et al. 2006; Sastry et al. 2013).
Menadione is a known substrate of NQO2 (Ferry et al. 2010). PQ, Mel and menadione
were used as a reference compound in this study so that the glide gscore and interaction profile of
these reference compound can be compared with PQ metabolites. The knowledge generated
through this analysis would help to understand that how the PQ metabolites bind/interact with the
protein, whether PQ metabolites bind like an inhibitor or like a substrate.

3.4.6. Statistical analysis.
Similar to chapter 2 section 2.4.5.

3.5. RESULTS
3.5.1. Methemoglobin formation
The washed normal and G6PDd human erythrocytes were incubated with the test
compounds at 370C for an hour and then analyzed with co-oximeter to determine methemoglobin.
Exposure of erythrocytes to oxidative reactions converts the Fe +2 oxyhemoglobin to Fe+3
methemoglobin, which loses the oxygen carrying capacity. The elevation in blood methemoglobin
levels, referred as methemoglobinemia, is an important diagnostic marker for oxidative stress. Co69

treatment of human erythrocytes with NQO2 inhibitors (Mel, Res, and Quer) caused a robust
elevation in metabolites (5-HPQ, 5,6-OQPQ, and MHQ) induced- methemoglobin formation.
Mel caused significant increase in 5-HPQ-induced methemoglobin formation in both
normal and G6PDd erythrocytes at 6.25, 12.5 and 25 µM concentration of 5-HPQ (Figure 3.2.A
and 3.2.B). Res and Quer considerably increased in 5-HPQ-induced methemoglobin formation in
both normal and G6PDd erythrocytes at all concentration (3.125-25 µM) of 5-HPQ (3.2.C and
3.2.D, 3.2.E and 3.2.F). These results indicate that all three NQO2 inhibitors (Mel, Res, and Quer)
increased 5-HPQ-induced methemoglobin.
Mel, Res, and Quer caused a significant increase in 5,6-OQPQ-induced methemoglobin
formation in both normal and G6PDd erythrocytes at all concentrations (3.125-25 µM) of 5,6OQPQ (Figure. 3.3). These results suggest that NQO2 inhibitors (Mel, Res, and Quer) augment
methemoglobinemia induced by 5,6-OQPQ.
Mel, Res, and Quer significantly increased MHQ-induced methemoglobin formation in
both normal and G6PDd erythrocytes at all concentrations (3.125-25 µM) of 5,6-OQPQ (Figure.
3.4). These results show that NQO2 inhibitors (Mel, Res, and Quer) augment methemoglobinemia
induced by MHQ.
Thus, the results indicate that NQO2 inhibitors (Mel, Res, and Quer) intensified
methemoglobinemia induced by PQ metabolites (5-HPQ, 5,6-OQPQ, and MHQ) in normal and
G6PDd erythrocytes. Moreover, Quer alone caused a significant increase in methemoglobin
accumulation (Figure 3.2.E, 3.2.F, 3.3.E, 3.3.F, 3.4.E and 3.4.F) and suggested that Quer forms
methemoglobin in normal and G6PDd erythrocytes.
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Figure 3.2: Methemoglobin formation due to treatment with 5-HPQ (A, B, C, D, E and F), 5-HPQ
+ Mel (A and B), 5-HPQ + Res (C and D) and 5-HPQ + Quer in (E and F) normal and (B, D and
F) G6PDd human erythrocytes. Each data point represents mean ± SE of at least duplicate
observations. The results were statistically analyzed with GraphPad Prism® with two-way
ANOVA followed by Tukey’s multiple comparison test and P values <0.05 were considered as
statistically significant. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 compared with 5HPQ-treated erythrocytes at corresponding concentration.
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Figure 3.3: Methemoglobin formation due to treatment with 5,6-OQPQ (A, B, C, D, E and F),
5,6-OQPQ + Mel (A and B), 5,6-OQPQ + Res (C and D) and 5,6-OQPQ + Quer in (E and F)
normal and (B, D and F) G6PDd human erythrocytes. Each data point represents mean ± SE of at
least duplicate observations. The results were statistically analyzed with GraphPad Prism® with
two-way ANOVA followed by Tukey’s multiple comparison test and P values <0.05 were
considered as statistically significant. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
compared with 5,6-OQPQ -treated erythrocytes at corresponding concentration.
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Figure 3.4: Methemoglobin formation due to treatment with MHQ (A, B, C, D, E and F), MHQ
+ Mel (A and B), MHQ + Res (C and D) and MHQ + Quer in (E and F) normal and (B, D and F)
G6PDd human erythrocytes. Each data point represents mean ± SE of at least duplicate
observations. The results were statistically analyzed with GraphPad Prism® with two-way
ANOVA followed by Tukey’s multiple comparison test and P values <0.05 were considered as
statistically significant. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 compared with
MHQ-treated erythrocytes at corresponding concentration.
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3.5.2. Generation of reactive oxygen species (ROS)
To determine the effect of NQO2 inhibitors (Mel, Res, and Quer) on oxidative stress caused
by PQ metabolites (5-HPQ, 5,6-OQPQ, and MHQ), the reactive oxygen species (ROS) generation
in both normal and G6PDd human erythrocytes was measured using the fluorescent dye, DCFDA.
Co-treatment of Mel increased generation of oxidative stress (increase in ROS) caused by 5-HPQ
in normal and G6PDd human erythrocytes at all the concentrations, (3.125-25 µM) of 5-HPQ
(Figure 3.5.A and 3.5.B). Res partially subsided ROS generated by 5-HPQ in normal erythrocytes
and G6PDd human erythrocytes at all the concentrations (3.125-25 µM) of 5-HPQ (Figure 3.5.C
and 3.5.D ). Quer had a dual effect on 5-HPQ-induced ROS generation in both erythrocytes. Quer
increased ROS induced by a lower concentration of 5-HPQ in normal (3.125 µM) and G6PDd
(3.125 and 6.25 µM) erythrocytes (Figure 3.5.E and 3.5.F). However, Quer partially attenuated
ROS caused by the higher concentration of 5-HPQ in normal (12.5 and 25 µM) and G6PDd (25
µM) erythrocytes (Figure 3.5.E and 3.5.F). Additionally, treatment of Quer alone produced a
significant increase in ROS in normal and G6PDd erythrocytes as compared to vehicle control
(Figure 3.5.E and 3.5.F).
Co-exposure of Mel with 5,6-OQPQ potentiated oxidative stress generated due 5,6-OQPQ
alone in normal and G6PDd human erythrocytes at all the concentrations (3.125-25 µM) of 5,6OQPQ (Figure 3.6.A and 3.6.B). Res partially attenuated oxidative stress produced by 5,6-OQPQ
in G6PDd erythrocytes at 25 µM concentrations of 5,6-OQPQ (Figure 3.6.D). Similarly, Res
partially attenuated oxidative stress produced by 5,6-OQPQ in normal erythrocytes. However, the
effect of Res is not statistically significant (Figure 3.6.C). Quer increased ROS induced by 5,6OQPQ in normal and G6PDd at 3.125 - 12.5 µM concentrations of 5,6-OQPQ (Figure 3.6.E and
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3.6.F). Furthermore, exposure of Quer alone generated a significant increase in ROS in normal
and G6PDd erythrocytes as compared to vehicle control (Figure 3.6.E and 3.6.F).
Co-exposure of Mel with MHQ potentiated oxidative stress generated due to MHQ alone
in normal and G6PDd human erythrocytes at all the concentrations (3.125 - 25 µM) of MHQ
(Figure 3.7.A and 3.7.B). Res and Quer partially attenuated oxidative stress produced by MHQ
alone in normal and G6PDd human erythrocytes at all the concentrations (3.125 - 25 µM) of MHQ
(Figure. 3.7).
Thus, the results indicate that Mel potentiates oxidative stress induced by PQ metabolites
(5-HPQ, 5,6-OQPQ, and MHQ) in normal and G6PDd erythrocytes. However, in normal and
G6PDd erythrocytes, Res partially attenuate oxidative stress generated by PQ metabolites (5-HPQ,
5,6-OQPQ, and MHQ). Quer had the ability to generate oxidative stress in normal and G6PDd
erythrocytes. Like Res, Quer also partially attenuate PQ-metabolites-induced oxidative stress in
human erythrocytes.
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Figure 3.5: ROS generation due to treatment with 5-HPQ (A, B, C, D, E and F), 5-HPQ + Mel (A
and B), 5-HPQ + Res (C and D) and 5-HPQ + Quer in (E and F) normal and (B, D and F) G6PDd
human erythrocytes at 120 minutes. Each data point represents mean ± SE of at least duplicate
observations. The results were statistically analyzed with GraphPad Prism® with two-way
ANOVA followed by Tukey’s multiple comparison test and P values <0.05 were considered as
statistically significant. **p < 0.01, ***p < 0.001, ****p < 0.0001 compared with 5-HPQ-treated
erythrocytes at corresponding concentration. RFU- Relative fluorescence unit.
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Figure 3.6: ROS generation due to treatment with 5,6-OQPQ (A, B, C, D, E and F), 5,6-OQPQ +
Mel (A and B), 5,6-OQPQ + Res (C and D) 5,6-OQPQ 5-HPQ + Quer in (E and F) normal and (B,
D and F) G6PDd human erythrocytes at 120 minutes. Each data point represents mean ± SE of at
least duplicate observations. The results were statistically analyzed with GraphPad Prism® with
two-way ANOVA followed by Tukey’s multiple comparison test and P values <0.05 were
considered as statistically significant. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
compared with 5,6-OQPQ -treated erythrocytes at corresponding concentration. RFU- Relative
fluorescence unit.
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Figure 3.7: ROS generation due to treatment with MHQ (A, B, C, D, E and F), MHQ + Mel (A
and B), MHQ + Res (C and D) and MHQ + Quer in (E and F) normal and (B, D and F) G6PDd
human erythrocytes at 120 minutes. Each data point represents mean ± SE of at least duplicate
observations. The results were statistically analyzed with GraphPad Prism® with two-way
ANOVA followed by Tukey’s multiple comparison test and P values <0.05 were considered as
statistically significant. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 compared with MHQtreated erythrocytes at corresponding concentration. RFU- Relative fluorescence unit.
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3.5.3. Estimation of intraerythrocytic reduced glutathione (GSH) levels.
To estimate the effect of NQO2 inhibitors (Mel, Res, and Quer) on PQ metabolite (5-HPQ,
5,6-OQPQ, and MHQ) induced-GSH depletion in normal and G6PDd human erythrocytes, an
enzymatic luciferase assay was used. Co-treatment of NQO2 inhibitors (Mel, Res, and Quer) with
PQ metabolites (5-HPQ, 5,6-OQPQ, and MHQ) did not have any significant effect on GSH level
as compared to that of PQ metabolites (5-HPQ, 5,6-OQPQ, and MHQ) alone in normal
erythrocytes (Figure 3.8, 3.9 and 3.10).
Co-treatment of NQO2 inhibitors (Mel, Res, and Quer) with 5-HPQ caused further
depletion in GSH level as caused by 5-HPQ alone in G6PDd human erythrocytes. However, this
effect is not significant (Figure 3.8). Similarly, co-exposure of NQO2 inhibitors (Mel, Res, and
Quer) with 5,6-OQPQ caused further depletion in GSH level as caused by 5,6-OQPQ alone in
G6PDd human erythrocytes. However, this effect is not significant (Figure 3.9). Though, coexposure of NQO2 inhibitors (Mel, Res, and Quer) with MHQ did not have any significant effect
on GSH level as compared to that of MHQ alone in normal erythrocytes (Figure 3.10).
These results suggest that cotreatment of NQO2 inhibitors (Mel, Res, and Quer) with PQ
metabolites (5-HPQ, 5,6-OQPQ and MHQ) had no significant effect on PQ metabolites-induced
depletion in GSH levels in normal and G6PDd human erythrocytes.
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Figure 3.8: Intraerythrocytic GSH levels due to treatment with 5-HPQ (A, B, C, D, E and F), 5HPQ + Mel (A and B), 5-HPQ + Res (C and D) and 5-HPQ + Quer in (E and F) normal and (B, D
and F) G6PDd human erythrocytes. Each data point represents mean ± SE of at least duplicate
observations. The results were statistically analyzed with GraphPad Prism® with two-way
ANOVA followed by Tukey’s multiple comparison test and P values <0.05 were considered as
statistically significant. *p < 0.05 compared with 5-HPQ-treated erythrocytes at corresponding
concentration.
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Figure 3.9: Intraerythrocytic GSH levels due to treatment with 5,6-OQPQ (A, B, C, D, E and F),
5,6-OQPQ + Mel (A and B), 5,6-OQPQ + Res (C and D) and 5,6-OQPQ + Quer in (E and F)
normal and (B, D and F) G6PDd human erythrocytes. Each data point represents mean ± SE of at
least duplicate observations. The results were statistically analyzed with GraphPad Prism® with
two-way ANOVA followed by Tukey’s multiple comparison test and P values <0.05 were
considered as statistically significant. **p < 0.01 compared with vehicle control erythrocytes at
corresponding concentration.
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Figure 3.10: Intraerythrocytic GSH levels due to treatment with MHQ (A, B, C, D, E and F),
MHQ + Mel (A and B), MHQ + Res (C and D) and MHQ + Quer in (E and F) normal and (B, D
and F) G6PDd human erythrocytes. Each data point represents mean ± SE of at least duplicate
observations. The results were statistically analyzed with GraphPad Prism® with two-way
ANOVA followed by Tukey’s multiple comparison test and P values <0.05 were considered as
statistically significant.
82

3.5.4. Estimation of intraerythrocytic total glutathione levels.
Total intraerythrocytic glutathione level was also measured by enzymatic luciferase assay
using TCEP as reducing agent to thiol (Winther and Thorpe 2014). The results showed that cotreatment of NQO2 inhibitors (Mel, Res and Quer) with PQ metabolites (5-HPQ, 5,6-OQPQ and
MHQ) did not have any significant effect on total GSH level as compared to that of PQ metabolites
(5-HPQ, 5,6-OQPQ and MHQ) alone in normal and G6PDd human erythrocytes (Figure 3.11 Figure 3.13).
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Figure 3.11: Intraerythrocytic total GSH levels due to treatment with 5-HPQ (A, B, C, D, E and
F), 5-HPQ + Mel (A and B), 5-HPQ + Res (C and D) and 5-HPQ + Quer in (E and F) normal and
(B, D and F) G6PDd human erythrocytes. Each data point represents mean ± SE of at least
duplicate observations. The results were statistically analyzed with GraphPad Prism® with twoway ANOVA followed by Tukey’s multiple comparison test and P values <0.05 were considered
as statistically significant.
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Figure 3.12: Intraerythrocytic total GSH levels due to treatment with 5,6-OQPQ (A, B, C, D, E
and F), 5,6-OQPQ + Mel (A and B), 5,6-OQPQ + Res (C and D) and 5,6-OQPQ + Quer in (E and
F) normal and (B, D and F) G6PDd human erythrocytes. Each data point represents mean ± SE of
at least duplicate observations. The results were statistically analyzed with GraphPad Prism® with
two-way ANOVA followed by Tukey’s multiple comparison test and P values <0.05 were
considered as statistically significant. ***p < 0.001 compared with 5,6-OQPQ-treated erythrocytes
at corresponding concentration.
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Figure 3.13: Intraerythrocytic total GSH levels due to treatment with MHQ (A, B, C, D, E and F),
MHQ + Mel (A and B), MHQ + Res (C and D) and MHQ + Quer in (E and F) normal and (B, D
and F) G6PDd human erythrocytes. Each data point represents mean ± SE of at least duplicate
observations. The results were statistically analyzed with GraphPad Prism® with two-way
ANOVA followed by Tukey’s multiple comparison test and P values <0.05 were considered as
statistically significant.
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3.5.5. Determination of phosphatidylserine exposure in human erythrocytes.
The flow cytometric assay employing FITC Annexin V binding assay was used to
determine phosphatidylserine externalization in normal and G6PDd erythrocytes. Translocation of
phosphatidylserine on the outer membrane of erythrocytes due to treatment with 5,6-OQPQ (25
µM) alone and in combination with Quer (100 µM) and a comparative evaluation of translocation
of phosphatidylserine in normal and G6PDd erythrocytes due to 5,6-OQPQ and 5,6-OQPQ + Quer
exposure was done. Quer alone did not have any significant effect on phosphatidylserine
externalization in normal and G6PDd erythrocytes (Figure 3.14). Treatment with 5,6-OQPQ and
5,6-OQPQ + Quer significantly induced phosphatidylserine externalization in both normal and
G6PDd erythrocytes. Treatment with 5,6-OQPQ and 5,6-OQPQ + Quer induced significantly
higher phosphatidylserine externalization in G6PDd as compared to normal erythrocytes (Figure
3.14). Thus, these results suggest that 5,6-OQPQ and 5,6-OQPQ + Quer caused externalization of
phosphatidylserine on the outer surface of G6PDd human erythrocytes. Co-exposure of Quer with
5,6-OQPQ did not have any additional effect on phosphatidylserine externalization caused by 5,6OQPQ alone in normal and G6PDd erythrocytes (Figure 3.14).
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Figure 3.14: Phosphatidylserine exposure induced by 5,6-OQPQ, Quer and 5,6-OQPQ+ Quer in
normal and G6PDd human erythrocytes with. Each data point represents mean ± SE of at least
duplicate observations. The results were analyzed with GraphPad Prism® with two-way ANOVA
followed by Tukey’s multiple comparison test and P values <0.05 were considered as statistically
significant. *p < 0.05, ****p < 0.0001 compared with corresponding erythrocyte and vehicle
control. ap < 0.0001 compared with normal human erythrocytes exposed to corresponding
treatment (within group).
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3.5.6. Computational docking.
(Leung and Shilton 2013) demonstrated the involvement and importance of watermediated interactions of PQ with the NQO2 enzyme. Also, the presence of water molecules plays
an important role in the prediction of accurate poses/orientation of ligand−protein interactions.
Therefore, the water molecules in the crystal structure near 5Å of ligand binding site were kept.
The docking of primaquine (PQ), PQ metabolites (5-HPQ, 5,6-OQPQ, and MHQ), menadione and
melatonin using Glide employing extra precision (XP) docking method. PQ, Mel (NQO2
inhibitor), and menadione (NQO2 substrate) were used as reference compounds for this study. The
docking pose of PQ in our study showed the identical binding pose as shown in NQO2-primaquine
X-ray structure (4FGJ) (Figure 15). Further protein-ligand interactions study from docking
confirmed that PQ occupied the identical active site pocket and interacted with the key binding
site residues. The docking pose and interactions of menadione with NQO2 also matches with the
2QR2 crystal structure. This confirmed that the parameters set for Glide-XP docking mode were
reliable. The Glide gscores and binding free energies of preferred binding poses of ligands with
protein (4FGJ) are shown in Table 3.1. Glide gscore is a scoring function which approximates the
ligand binding free energy. The more negative ligand binding free energy suggests tighter binding
between ligand and protein. These computational docking results demonstrated that water
molecules play an important role in the interaction between ligands and human NQO2.
Glide gscores and binding free energies of PQ (Isomers; R and S) indicates that PQ has
strong binding affinity towards NQO2 compared to melatonin (Table 3.1). These results were
consistent with experimental results (Ki of PQ = 1.04 µM and IC50 of Mel = 41.5 µM) (Ferry et
al. 2010; Graves et al. 2002). However, the PQ metabolite, R/S-5-HPQ showed slightly better
docking scores compared to R/S- PQ, which suggests R/S-5-HPQ may have slightly better binding
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with NQO2 compared to PQ.
The preferred binding poses of R/S-5-HPQ, R/S-PQ, S-PQ, R/S-5,6-OQPQ and MHQ in
human NQO2 are shown in Figure 3.15. A detailed observation indicates that two water
participates in the interaction between R/S-5-HPQ and NQO2 protein. R/S-5-HPQ interacted via
water-mediated hydrogen-bond between the nitrogen of quinoline ring with ASN161 and another
water-mediated hydrogen-bond between protonated amine (side chain) of R/S-5-HPQ and GLN
122. A hydrogen bond between protonated amine (side chain) of R/S-5-HPQ and GLU 193 was
also observed (Figure 3.16). The quinoline ring of R-PQ displayed π-π stacking with TRP 105 and
PHE 178. The protonated amine of the side chain of R-PQ formed salt bridge interactions with
GLU 193. The protonated amine of the side chain of R-PQ also formed a hydrogen bond with a
water molecule. (Figure 3.17.A). The quinoline ring of S-PQ displayed π-π stacking with TRP 105.
S-PQ interacted via water-mediated hydrogen- bonding between the nitrogen of quinoline ring
with ASN161 and an additional water-mediated hydrogen- bonding between protonated amine
(side chain) of S-PQ and GLN 122 was also observed. A hydrogen bonding between protonated
amine (side chain) of S-PQ and GLU 193 was also seen (Figure 3.17.B).
The quinoline ring of R/S-5,6-OQPQ displayed π-π stacking with TRP 105. The oxygen
atom present at the 6th position of quinoline ring in R/S-5,6-OQPQ interacted with ASN161 via
water-mediated hydrogen-bonding. The protonated amine of the side chain of R/S-5,6-OQPQ
formed another water-mediated hydrogen- bonding with GLN 122 and a hydrogen bond with GLU
193 (Figure 3.18). The docking pose of Mel exhibited π-π stacking with indole ring and TRP 105,
and an H-bond between the oxygen of acyl group of the side chain of Mel and backbone of GLN
121 was observed (Figure 3.19). Menadione, also known as vitamin K3, exhibited strong
hydrophobic interactions with Trp105, Phe106, Phe126, and Phe178. Menadione also interacted
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with ASN161 and carbonyl oxygen at the C1 position via water-mediated H-bonding (Figure 3.20).
The docking pose of our study matches well with the pose reported in human quinone reductase
type 2, complex with menadione (PDB ID: 4FGJ).
The superimposition of most preferred binding poses of 5-HPQ and Mel in the binding
pocket of NQO2 suggest that they both bind in the similar orientation and the aromatic rings of 5HPQ and Mel were parallel to isoalloxazine ring of FAD (Figure 3.19). Careful observation of
most preferred binding poses of other PQ metabolites suggests that other PQ metabolites orient in
a similar fashion as S-PQ and Mel and one of the aromatic rings of these metabolites was parallel
to isoalloxazine ring of FAD (Figure. 3.15, 3.21 and 3.22). These results indicate that like PQ,
these metabolites of PQ may have a stronger binding affinity towards NOQ2 enzyme.
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Table 3.1: The docking scores of best binding poses of PQ, PQ metabolites, and Melatonin in a
human NQO2 protein having water molecules in their binding pocket.
Ligands

Glide gscore (kcal/mol)

Prime MM-GBSA dG binding
(kcal/mol)

R-5-HPQ

−8.514

−68.039

S-5-HPQ

−8.389

−69.046

R-PQ

−8.313

−68.658

S-PQ

−8.290

−69.425

S-5,6-OQPQ

−7.300

−55.127

R-5,6-OQPQ

−7.268

−55.120

MHQ

−6.564

−50.514

Melatonin

−6.431

−63.846

Menadione

−5.957

−39.439
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Figure 3.15: The most preferred binding poses of (A) R-5-HPQ (carbon in maroon) and S-5HPQ (carbon in plum), (B) R-PQ (carbon in turquoise) and S-PQ (carbon in yellow) and (C) R5,6-OQPQ (carbon in grey) and S-5,6-OQPQ (carbon in purple) and (D) MHQ (carbon in pink)
with NQO2.
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Figure 3.16: The 2D interactions of the most preferred binding pose of (A) R-5-HPQ and (B) S5-HPQ.
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Figure 3.17: The 2D interactions of the most preferred binding pose of (A) R-PQ, and (B) S-PQ.
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Figure 3.18: The 2D interactions of the most preferred binding pose of (A) R-5,6-OQPQ, and
(B) S--5,6-OQPQ.

96

Figure 3.19: The 2D interactions diagram of the most preferred binding pose of melatonin
(Mel).
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Figure 3.20: The 2D interactions diagram of the most preferred binding pose of menadione.
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Figure 3.21: Overlay of superimposed poses of melatonin (carbon in turquoise, ball and stick
model) and S-PQ (carbon in yellow, ball and stick model) after docking in NQO2 (4FGJ). FAD
is shown in carbon in blue. Chain B (green) and chain A (red) are represented in cartoon
representations.
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Figure 3.22: Overlay of superimposed poses of (A) R-5-HPQ (carbon in maroon), S-5-HPQ
(carbon in plum), R-PQ (carbon in turquoise), S-PQ (carbon in yellow), R-5,6-OQPQ (carbon in
grey), S-5,6-OQPQ (carbon in purple), and MHQ (carbon in pink) and (B) melatonin (carbon in
turquoise), S-PQ (carbon in yellow) and menadione (carbon in orange) after docking in NQO2
(4FGJ). FAD is shown in carbon in blue. Chain B (green) and chain A (red) are represented in
cartoon representations.
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3.6. DISCUSSION
NQO2 is an FAD-linked oxidoreductive enzyme that catalyzes mandatory two-electron
reductions of quinone to hydroquinones without forming highly reactive semiquinones and free
radicals (Foster et al. 2000; Vella et al. 2005). The NQO2 acts as a detoxification enzyme for
quinones (Graves et al. 2002). Quinones are redox active molecules and involve in a redox cycle
with their semiquinone radicals. This redox cycling causes generation of superoxide radicals.
Production of ROS leads to oxidative stress within the cells and causes oxidation of cellular
macromolecules, including DNA, lipids, and proteins (Bolton et al. 2000). Human erythrocytic
NQO2 is the only protein target identified for PQ (Ki-1.04±0.38 µM) (Graves et al. 2002; Murce
et al. 2015). However, the potential implications of binding of PQ with NQO2 in efficacy and/or
toxicity of PQ are not very clear. Previous kinetics studies demonstrated that PQ preferentially
binds to the oxidized state of NQO2 and shows competitive inhibition against the electron donating
co-factor dihydronicotinamide riboside (NRH), and FADH2 (Leung and Shilton 2013).
Current studies are focused on investigating the function of NQO2, a cytosolic flavoprotein
enzyme involved in metabolic detoxification/activation of hemotoxic metabolites of PQ, in PQinduced hemolytic anemia. In this study, the selective and potent inhibitors of NQO2 namely,
melatonin (Mel) (IC50 = 41.5±1.5µM), resveratrol (Res) (IC50 = 0.143±0.05 µM) and quercetin
(Quer) (IC50 = 1.4±0.1 µM) (Ferry et al. 2010; Boutin et al. 2005) were used as the probes to
understand the hemolytic toxicity of PQ. Studies were further extended to investigate the
interactions between crystal structure of human NQO2 (PBD: 4FGJ) and PQ metabolites (5-HPQ,
5,6-OQPQ, and MHQ) using computational molecular docking approach.
Mel potentiated the hemotoxicity when the human erythrocytes were cotreated with PQ
metabolites and Mel. Mel cotreatment increased 5-HPQ, 5,6-OQPQ and MHQ
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induced

methemoglobin accumulation and oxidative stress generation in normal as well as G6PDd
erythrocytes. Mel also potentiated GSH depletion caused by 5-HPQ, 5,6-OQPQ selectively in
G6PDd erythrocytes only. Similarly, Res cotreatment with also augmented 5-HPQ, 5,6-OQPQ and
MHQ induced methemoglobin accumulation. Res partially attenuated 5-HPQ, 5,6-OQPQ and
MHQ induced oxidative stress in both normal and G6PDd erythrocytes. This effect of resveratrol
may be due its antioxidant properties (Farris et al. 2013; Zhang et al. 2014). Res did not potentiate
GSH depletion caused by 5-HPQ and 5,6-OQPQ selectively in G6PDd erythrocytes. Quer showed
hemolytic toxicity properties. It significantly increased methemoglobin and generated oxidative
stress in normal and G6PDd erythrocytes and caused depletion in GSH levels selectively in G6PDd
erythrocytes. Quer co-treatmnet synergistically increased 5-HPQ, 5,6-OQPQ and MHQ induced
methemoglobin accumulation and did not cause further depletion in GSH levels caused by 5-HPQ,
5,6-OQPQ alone. Quer did not significantly increase PS exposure caused by 5,6-OQPQ. Earlier
investigation have shown that quercetin oxidizes oxyhemoglobin and causes lysis of human
erythrocyte (Galati et al. 2002). Quer is converted to oxidant products when act as an antioxidant
and scavenges free radicals (Boots et al. 2007). The oxidant quinoid product(s) further results in
the formation of superoxide ions, show high reactivity toward thiols and thus arylates glutathione
and protein thiol groups. This further leads to depletion of glutathione, and impairs functions of
several vital enzymes like glutathione reductase (Boots et al. 2003; Boots et al. 2007; Choi et al.
2003; Galati et al. 2002; Metodiewa et al. 1999). The results of the current study suggest that cotreatment of erythrocytes with NQO2 inhibitors and PQ metabolites potentiated the hemotoxicity
compared to treatment with PQ metabolites alone. Redox cycling of quinone and quinone-imine
metabolites have been implicated in hemotoxicity of PQ (Marcsisin et al. 2016). This suggests the
potential role of NQO2 in detoxification of reactive metabolites of PQ from erythrocytes. Thus,
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inhibiting NQO2 through potent and selective inhibitors of NQO2 is likely to alter the hemolytic
toxicity of PQ metabolites.
The computational docking results suggested that the presence of water molecules in the
binding pocket of NQO2 played critical role in binding of PQ and its metabolites with NQO2.
The importance of water molecule in binding between NQO2 enzyme and PQ has been
demonstrated earlier (Leung and Shilton 2013). Mel, Menadione, PQ and PQ metabolites bind at
the same binding pocket with slight variations. The glide gscores suggest that PQ and its
metabolites may have a better affinity towards NQO2 as compared to Mel and menadione.
The biochemical results showed that in the presence of NQO2 inhibitors, the hemolytic
toxicity caused by PQ metabolites is potentiated. The computational docking results suggest that
PQ metabolites interact with NQO2 better that Mel and Menadione. Since in the presence of NQO2
inhibitors, the toxicity is increased which suggest the protective role of the NQO2 enzyme. Based
on biochemical and computational docking results, we believe that PQ metabolites might act as
the substrates and NQO2 may be involve in the detoxification of PQ metabolites. These studies
suggest protective role of NQO2 against PQ-induced hemolytic toxicity.
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CHAPTER 4
METABOLOMIC PROFILE OF NORMAL AND GLUCOSE-6-PHOSPHATE
DEHYDROGENASE DEFICIENT ERYTHROCYTES TREATED WITH PRIMAQUINE
METABOLITES.

4.1. INTRODUCTION & RATIONALE
Metabolites are small compounds, produced during metabolism and depict the functional
readouts of cellular and biochemical states (Patti et al. 2012). The collection of metabolites within
a cell, tissue, organ or biological fluid is known as metabolome (Patti et al. 2012). By analyzing
the qualitative and quantitative profiles of the cellular metabolites, biochemical activity of the cell
can be determined. Disease states and drug treatments alter biochemical pathways, which can be
assessed through either targeted or untargeted comparative metabolomic workflows (Patti et al.
2012; Kaddurah-Daouk et al. 2008).
As mentioned earlier, the GSH-centered antioxidant functions are severely compromised
in G6PDd individuals (Judith Recht 2014; Mason et al. 2007). Primaquine (PQ) generates
oxidative stress in the erythrocytes, which is primarily initiated by the PQ metabolites produced
through CYP-mediated pathways (Ganesan et al. 2009; Ganesan et al. 2012). However, the
interplay between hemolysis, G6PD deficiency, ROS, and GSH is more complicated (Tang et al.
2015). These findings necessitate examination of the metabolomes of normal and G6PDd human
erythrocytes and also PQ-mediated changes in the metabolomes of normal and G6PDd human
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erythrocytes. Thus, to explore potential mechanism(s) of PQ-induced hemolysis in G6PDd human
erythrocytes, in vitro experiments with normal and G6PDd human erythrocytes treated with PQ
metabolites were done to mimic the in vivo conditions during hemolytic anemia induced by PQ
treatment and comparative untargeted metabolomics analyses were performed.

4.2. HYPOTHESIS
PQ metabolite, 5,6-orthoquinone primaquine (5,6-OQPQ) will alter the metabolite profile
in normal and G6PDd erythrocytes. These changes will mechanistically support the
pathophysiology of hemolysis in G6PDd erythrocytes.

4.3. OBJECTIVE
In this study, the changes in global cellular metabolism and compensatory responses in
biochemical pathways of cellular metabolism in response to 5,6-OQPQ, metabolite of PQ were
assessed using an untargeted metabolomic workflow. The conventional biochemical approach
often concentrates on a single metabolite, one metabolic reaction, or a limited set of linked
reactions and cycles. In contrast to the conventional biochemical approach, an untargeted LC-MS
based metabolomic approach involves the simultaneous collection of qualitative and (relative)
quantitative data for as many metabolites as possible to obtain insight into metabolism associated
with conditions of interest, including disease state and drug exposure (Kaddurah-Daouk et al.
2008). Also, metabolomics is thought to be a valuable tool for biomarker discovery, and in contrast
to conventional clinical biomarkers and classical diagnostic approaches, metabolomics poses
potential benefits in feasibility, specificity, and sensitivity (Kaddurah-Daouk et al. 2008). Thus, a
global untargeted metabolomic approach may aid in discovery of new biomarkers for G6PD
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deficiency and PQ-induced hemolysis in normal and G6PDd erythrocyte.

4.4 MATERIALS AND METHODS.
4.4.1. Chemicals
LC-MS grade methanol and water were purchased from Fisher Scientific (Waltham, MA,
USA). 5,6-OQPQ was synthesized by Dr. N.P. Dhammika Nanayakkara at the National Centre for
Natural Products Research (NCNPR), University of Mississippi.

4.4.2. Procurement of human blood
Blood was drawn from normal and glucose 6-phosphate dehydrogenase deficient (G6PDd)
healthy volunteers in tubes containing citrate phosphate under an institutional review board (IRB)
approved protocol.
To analyze metabolite profiling of normal and G6PDd human erythrocytes, blood from
four different batches was used. For three batches, G6PDd blood was taken from Caucasian male
containing the Ser188Phe Mediterranean mutation and for one batch, G6PDd blood was taken
from African American male carrying the classic A/A- combination of electrophoretic variant
(Asn126Asp) and deficiency allele (Val68Met).
To analyze the effect of 5,6-OQPQ, on global metabolomics profile of normal and G6PDd
erythrocytes, G6PDd blood was taken from a Caucasian male containing the Ser188Phe
Mediterranean mutation from a single batch.

4.4.3. Sample preparation for metabolomic analysis
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For untargeted metabolomics experiments of normal and G6PDd human
erythrocytes, the blood was centrifuged at 4500 × g at 40C for 10 minutes, and buffy coats were
removed. The erythrocyte pellets were washed twice with phosphate buffered saline (110 mM
sodium chloride, 20 mM disodium hydrogen phosphate and 4 mM potassium dihydrogen
phosphate, pH 7.4). The aliquots (250 µL each) of washed erythrocytes pellets were stored at 800C for further processing. The erythrocytes aliquots (250 µL) were removed from -80 0C freezer
and lysed with 750 µL of cold acetonitrile: methanol: ammonium Bicarbonate (0.1 M, pH 8.0)
(1:1:2) lysis buffer. The pellets were vortexed for 10 seconds, froze in liquid nitrogen for 10
seconds, defrosted for 10 minutes and sonicated with a probe tip at 10 pulses. This step was
repeated 3 times. Ice-cold methanol (500 μL) was added to each pellet to precipitate proteins and
then incubated at -800C overnight. The samples were thawed, centrifuged (14000 × rpm at 4 0C
for 15 minutes) and the supernatants were transferred to separate tubes. The supernatants were
dried in a speed vac at low drying rate and kept at -800C until ready for metabolomics analysis.
To analyze the effect of 5,6-OQPQ on global metabolomic profiles of normal and G6PDd
erythrocytes, the blood was centrifuged at 4500 × g at 40C for 10 minutes, and buffy coats were
removed. The erythrocyte pellets were washed twice with phosphate buffered saline (110 mM
sodium chloride, 20 mM disodium hydrogen phosphate and 4 mM potassium dihydrogen
phosphate, pH 7.4). The washed erythrocytes pellets were then re-suspended at 50% hematocrit in
phosphate buffered saline (PBS). Normal and G6PDd human erythrocytes were treated with the
5,6-OQPQ (50 µM) for different time periods (0, 30, 60, 120 and 480 minutes). The reaction
mixture contained 200 µl erythrocytes which were suspended in PBS with 50% hematocrit, 10 µl
of 5,6-OQPQ and PBS to make a final volume of reaction mixture to 800 µl. The reaction mixture
with appropriate control without 5,6-OQPQ was also set up simultaneously. The reaction mixtures
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were incubated for 0, 30, 60, 120 and 480 minutes at 37 0C in a shaking water bath. The samples
were removed from the water bath and centrifuged at 15294 X g for 10 min at 4 0C. The
erythrocytes’ pellets were obtained from controls and 5,6-OQPQ treatments, flash frozen in liquid
nitrogen for 30 seconds and then stored at -800C for further processing. The samples were thawed
and 600 µL of chilled acetonitrile: methanol: ammonium bicarbonate (0.1 M, pH 8.0) (1:1:2) lysis
buffer was added to the erythrocyte’s pellets. The samples were vortexed for 10 seconds, frozen
in liquid nitrogen for 10 seconds, defrosted for 10 minutes, again vortexed for 10 seconds and
sonicated in sonicator bath, in the presence of ice for 5 minutes at a time. The protein in the samples
was precipitated using ice-cold methanol and then incubated at -80 0C overnight. The samples were
thawed, centrifuged (20817 × g at 4 0C for 15 minutes), and the supernatants were transferred to
fresh tubes. The supernatants were dried in a speed vac at low drying rate and kept at -80 0C until
ready to use.

4.4.4. UHPLC-MS analysis
The UHPLC-MS analysis was done by Dr. Alexandra Rutledge in Vanderbilt University.
For LC-MS analysis, dried samples were reconstituted in 100 μl of acetonitrile/ water (80:20, v/v)
and centrifuged for 5 min at 21130 X g to remove insoluble material. A quality control pool was
prepared from equal volumes of each experimental sample. This sample was used as one measure
of quality control during the experiment as well as for data-dependent acquisitions (DDA) for
feature annotation. Full MS and DDA experiments were performed on a Q-Exactive HF hybrid
quadrupole-Orbitrap mass spectrometer (Thermo Fisher Scientific, Bremen, Germany) equipped
with a Vanquish UHPLC binary system and autosampler (Thermo Fisher Scientific, Germany).
Extracts (5 µL injection volume) were separated on a SeQuant ZIC-p HILIC 5-μm, 2.1 mm × 150
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mm column (normal versus G6PDd samples) or SeQuant ZIC-HILIC 3.5-μm, 2.1 mm × 100 mm
column (Millipore Corporation, Darmstadt, Germany) (drug-dose-time course samples) held at
40°C. Liquid chromatography was performed at a 200 μl/min using solvent A (5mM Ammonium
formate in 90% water, 10% acetonitrile) and solvent B (5mM Ammonium formate in 90%
acetonitrile, 10% water) with the following gradient: 90% B for 2 minutes, 90-40% B over 16
minutes, 40% B held 2 minutes, and 40-90% B over 10 minutes, 90% B held 10 minutes.
Full MS analyses were acquired over a mass range of m/z 70-1050 under an ESI positive
profile mode with a resolution of 120000 and scan rate at ∼3.5 Hz. The automatic gain control
(AGC) target was set at 1 × 106 ions, and maximum ion injection time (IT) was at 100 ms. Source
ionization parameters were optimized with the spray voltage at 3.0 kV, and other parameters were
as follows: transfer temperature at 280°C; S-Lens level at 40; heater temperature at 325°C; Sheath
gas at 40, Aux gas at 10, and sweep gas flow at 1. Tandem spectra were acquired for quality control
pool samples (described above) using a data-dependent scanning mode in which one full MS scan
(m/z 70-1050) was followed by 2 MS/MS scans. MS/MS scans are acquired in profile mode using
an isolation width of 1.3 m/z, stepped collision energy (NCE 20, 40, 60), and a dynamic exclusion
of 6s. MS/MS spectra were collected at a resolution of 15000, with an automatic gain control
(AGC) target set at 2 × 105 ions, and maximum ion injection time (IT) of 100 ms.

4.4.5. Data processing
Raw data were imported, processed, normalized, and reviewed using Progenesis QI v.2.1
(Non-linear Dynamics, Newcastle, UK). All sample runs were aligned against a QC pool reference
run, and peak picking was performed on individual aligned runs to create an aggregate data set.
Features (retention time and m/z pairs) were combined using both adduct and isotope
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deconvolution. Data were normalized to all compounds. Principle Components Analysis (PCA)
was used to visualize clustering of data groups. Significance was assessed using p-values and fold
changes calculated from combined feature abundance data.
Tentative and putative annotations (Schrimpe-Rutledge et al. 2016) were made using
experimental accurate mass measurements (< 5 ppm error), isotope distribution similarity,
predicted formula (Compound Discoverer 2.0.0.303, Thermo) and fragmentation spectrum
matching by searching mzCloud, the Human Metabolome Database (HMDB), METLIN,
MassBank, Waters Metabolic Profiling CCS Library, and NIST 14 databases. Annotations were
filtered for endogenous small molecules present in the HMDB database and classified into
confidence levels based on supporting evidence. Level 2: putative identification match of
experimental accurate mass (mass tolerance ± 5 ppm), predicted formula, and MS/MS spectrum
to a spectral library, and Level 3: tentative structure match of experimental accurate mass (mass
tolerance ± 5 ppm) and predicted formula to HMDB database. The workflow proposed for
metabolite identification is shown in Figure 4.1 (Schrimpe-Rutledge et al. 2016).

4.4.6. Statistical analysis
For statistical analysis, ANOVA was performed in Progenesis QI v.2.1 (Non-linear
Dynamics, Newcastle, UK) and a p-value of less than 0.05 was considered significant.
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Figure 4.1: Proposed workflow for metabolite identification (Schrimpe-Rutledge et al. 2016).
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4.5. RESULTS
4.5.1 Different metabolic profile of normal and G6PDd erythrocytes:
To compare global metabolomic profiles, normal and G6PDd erythrocytes, the
erythrocytes were lysed and then analyzed by UHPLC-MS. Principal component analysis of the
metabolomic dataset showed clustering of untreated normal and G6PDd erythrocytes sample
groups (Figure 4.2). The raw data was processed and analyzed by Progenesis QI v.2. After
annotation, 87 metabolites were tentatively or putatively identified (Table 4.1). Pathway analysis
of these metabolites was performed using MetaboAnalyst 3.0, an open-source web application
(Figure. 4.3; Table 4.2) (Xia and Wishart 2016; Xia et al. 2015). When MetaboAnalyst is used to
analyze pathway of given metabolites, it matches all pathways on the basis of p values and pathway
impact values. The p values and pathway impacts values are calculated from pathway enrichment
analysis and pathway topology analysis respectively. In pathway analysis graphs, each circle
represents a pathway. As the pathway impact values increases, the size of circle increases and as
the p values increases the color of circle changes from yellow to red (yellow circle: p value less;
red circle: p values higher). Among 87 metabolites there were 29 metabolites which showed fold
change ≥ 1.5 in G6PDd erythrocytes as compared to normal erythrocytes (Figure. 4.4). There were
16 and 13 metabolites which were upregulated and downregulated in G6PDd erythrocytes (Figure
4.5 and Figure 4.6). The 29 metabolites which displayed fold change ≥ 1.5 in G6PDd erythrocytes
as compared to normal erythrocytes were also analyzed by MetaboAnalyst 3.0 to identify the major
pathways which were over-represented in G6PDd erythrocytes (Figure 4.7; Table 4.3).
Methylimidazole acetaldehyde, a histamine metabolite was significantly higher (14-fold)
in G6PDd erythrocytes (Figure 4.5) (Zimatkin and Anichtchik 1999). Carnitine and its derivative
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namely hydroxybutyrylcarnitine, heptadecanoylcarnitine, stearoylcarnitine, carnitine, and
propionylcarnitine were significantly higher in G6PDd erythrocytes (Figure 4.5). Carnitine and
derivatives of carnitine participate in lipid oxidation (Darghouth et al. 2011). Biotin amide and
trigonelline levels were increased in G6PDd (Figure 4.5). Levels of amino acids including leucine,
nor-leucine, aspartic acid and derivatives of amino acids namely homo-arginine, N(6)methyllysine and alpha-N-Phenylacetyl-L-glutamine were increased in G6PDd erythrocytes
(Figure 4.5). 5'-Methylthioadenosine and hypoxanthine were also upregulated in G6PDd
erythrocytes (Figure 4.5). 5'-Methylthioadenosine plays an important role in methionine, and
purine salvage pathways (Avila et al. 2004) and hypoxanthine is a byproduct of ATP catabolism
(Farthing et al. 2015).
Metabolites that participate in GSH pathway including GSH, ophthalmic acid, and
glutamic acid were significantly lower in G6PDd erythrocytes (Figure 4.6). Levels of an amino
acid such as asparagine and taurine, and metabolites of amino acid, for example, pipecolic acid, a
metabolite of lysine, was lower in G6PDd erythrocytes (Figure 4.6). Further, several metabolites
of fatty acid (N-decanoylglycine and N-undecanoylglycine) (Cruickshank-Quinn et al. 2014) and
of glycerophospholipid pathway including choline, neurine and LysoPC(16:0) were lower in
abundance (Gibellini and Smith 2010; Tweedie et al. 2006; Saito et al. 2014). AMP, the precursor
of ATP and ergothioneine, antioxidant and metabolite of histidine were also low in G6PDd
erythrocytes (Figure 4.6).
These

results

suggest

that

the

histidine,

GSH-Methionine-Glutamate,

purine,

glycerophospholipid and fatty acid oxidation pathways were greatly affected in G6PDd
erythrocytes.
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Figure 4.2: Metabolome changes in normal and G6PDd human erythrocytes in in normal-G6PDd
experiment. Data were analyzed in principal component analysis plot. The score plot for normal
(yellow) and G6PDd (blue) were shown (n=8). Each point represents an individual sample’s data
as a single unit. Clustering of the sample types shows the consistency of profiles between groups.
X axis represent principal component 1 (PCA 1) and Y axis represent principal component 2 (PCA
2).
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Table 4.1: The metabolites annotated (identified) in normal and G6PDd human erythrocytes in
normal-G6PDd experiment.
HMDB id
HMDB00034
HMDB00043
HMDB00045
HMDB00062
HMDB00064
HMDB00070
HMDB00086
HMDB00097
HMDB00112
HMDB00125
HMDB00128
HMDB00148
HMDB00157
HMDB00158
HMDB00159
HMDB00162
HMDB00167
HMDB00168
HMDB00172
HMDB00175
HMDB00177
HMDB00187
HMDB00191
HMDB00201
HMDB00210
HMDB00214
HMDB00222
HMDB00251
HMDB00267
HMDB00295
HMDB00479
HMDB00517
HMDB00562
HMDB00641
HMDB00670
HMDB00687

Metabolite name
Adenine
Betaine
Adenosine monophosphate
L-Carnitine
Creatine
Pipecolic acid
Glycerophosphocholine
Choline
Gamma-Aminobutyric acid
Glutathione
Guanidoacetic acid
L-Glutamic acid
Hypoxanthine
L-Tyrosine
L-Phenylalanine
L-Proline
L-Threonine
L-Asparagine
L-Isoleucine
Inosinic acid
L-Histidine
L-Serine
L-Aspartic acid
L-Acetylcarnitine
Pantothenic acid
Ornithine
L-Palmitoylcarnitine
Taurine
Pyroglutamic acid
Uridine 5'-diphosphate
3-Methylhistidine
L-Arginine
Creatinine
L-Glutamine
Homo-L-arginine
L-Leucine
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HMDB00696
HMDB00734
HMDB00824
HMDB00848
HMDB00875
HMDB00902
HMDB00904
HMDB00929
HMDB00961
HMDB01065
HMDB01173
HMDB01325
HMDB01341
HMDB01406
HMDB01458
HMDB01488
HMDB01511
HMDB01645
HMDB02005
HMDB02038
HMDB02064
HMDB02142
HMDB03045
HMDB03337

L-Methionine
Indoleacrylic acid
Propionylcarnitine
Stearoylcarnitine
Trigonelline
NAD
Citrulline
L-Tryptophan
Farnesyl pyrophosphate
2-Hydroxyphenethylamine
5'-Methylthioadenosine
N6,N6,N6-Trimethyl-L-lysine
ADP
Niacinamide
Biotin amide
Nicotinic acid
Phosphocreatine
L-Norleucine
Methionine sulfoxide
N(6)-Methyllysine
N-Acetylputrescine
Phosphoric acid
Ergothioneine
Oxidized glutathione

HMDB03431
HMDB03464
HMDB04181
HMDB04296
HMDB04827
HMDB05065
HMDB05066
HMDB05765
HMDB06210
HMDB06344
HMDB10382
HMDB10384
HMDB10386
HMDB10399
HMDB13127

L-Histidinol
4-Guanidinobutanoic acid
Methylimidazole acetaldehyde
Acrylamide
Proline betaine
Oleoylcarnitine
Tetradecanoylcarnitine
Ophthalmic acid
Heptadecanoyl carnitine
Alpha-N-Phenylacetyl-L-glutamine
LysoPC(16:0)
LysoPC(18:0)
LysoPC(18:2(9Z,12Z))
LysoPC(22:1(13Z))
Hydroxybutyrylcarnitine
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HMDB13131
HMDB13133
HMDB13267
HMDB13286
HMDB31259
HMDB31641
HMDB32231
HMDB32330
HMDB41809
HMDB60067
HMDB60363

Hydroxyhexanoycarnitine
Methylmalonylcarnitine
N-Decanoylglycine
N-Undecanoylglycine
Neurine
Pyrrolidine
Dimethylethanolamine
4-Hydroxy-2-butenoic acid gamma-lactone
4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol
CMP-2-aminoethylphosphonate
2,5-Dichloro-4-oxohex-2-enedioate
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Table 4.2: Major pathways identified using MetaboAnalyst 3.0 for 87 metabolites annotated in
normal and G6PDd human erythrocytes in normal-G6PDd experiment.
.
Pathway
Total
Hits
-Log (p)
Impact
Arginine and proline
77
14
18.32
0.51
Glycine, serine and threonine
48
8
10.10
0.26
Alanine, aspartate and glutamate
24
5
8.64
0.22
Histidine
44
7
7.74
0.79
Glutathione
38
5
5.57
0.25
Cysteine and methionine
56
5
3.94
0.10
Glycerophospholipid
39
4
3.78
0.03
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Figure 4.3: Pathway analysis of 87 metabolites identified between normal and G6PDd
erythrocytes using MetaboAnalyst 3.0 in normal-G6PDd experiment.
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Figure 4.4: Metabolite fold change in G6PDd erythrocytes versus normal erythrocytes. n = 4. Fold
change ≥ 1.5. Statistical differences between normal and G6PD-deficient cells were determined
by ANOVA. P values <0.05 were considered significant (*p < 0.05 and **p < 0.01).
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Figure 4.5: Metabolites which were upregulated (fold change ≥ 1.5) in G6PDd erythrocytes. In
the figure, from top to bottom is largest fold change to smallest. Each bar represents mean of 4
experiments, and each experiment had 2 technical replicates. x-axis = Log2 normalized abundance
scale. Statistical differences between normal and G6PDd erythrocytes were determined by
ANOVA. p-value ≤ 0.05; Error bars represent 95% confidence; Significance values * ≤ 0.05, ** ≤
0.01.
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Figure 4.6: Metabolites which were downregulated (fold change ≥ 1.5) in G6PDd erythrocytes.
In the figure, from top to bottom is largest fold change to smallest. Each bar represents mean of 4
experiments, and each experiment had 2 technical replicates. x-axis = Log2 normalized abundance
scale. Statistical differences between normal and G6PDd erythrocytes were determined by
ANOVA. p-value ≤ 0.05; Error bars represent 95% confidence; Significance values * ≤ 0.05, ** ≤
0.01.
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Figure 4.7: Pathway analysis of 29 metabolites that were altered more than 1.5-fold between
normal and G6PDd erythrocytes using MetaboAnalyst 3.0 in normal-G6PDd experiment.
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Table 4.3: Major pathways affected, identified using MetaboAnalyst 3.0 for 29 metabolites which
showed fold change ≥ 1.5 in G6PDd erythrocytes as compared to normal erythrocytes in normalG6PDd experiment.
Pathway name
Histidine
Alanine, aspartate and glutamate
Cysteine and methionine
Glutathione
Glycerophospholipid

Total
44
24
56
38
39

Hits
4
3
3
2
2

-Log (p)
7.48
6.73
4.31
3.07
3.03

Impact
0.018
0.48
0.05
0.24
0.024

4.5.2. Distinct metabolic profile of normal and G6PDd erythrocytes due to 5, 6-OQPQ
treatment.
To identify changes in cellular metabolism between normal and G6PDd
erythrocytes mediated by 5, 6-OQPQ treatment, both donor groups erythrocytes were treated with
25 µM 5, 6-OQPQ for 0, 30, 60, 120, and 480 minutes. The extractions of these erythrocytes were
analyzed by UHPLC-MS as previously described and the raw data was processed and analyzed by
Progenesis QI v.2. After annotation, total 111 metabolites were identified (Table 4.4). Further,
pathway overrepresentation analysis of these 111 metabolites was performed using MetaboAnalyst
3.0, an open-source web application (Figure. 4.8; Table 4.5) (Xia and Wishart 2016; Xia et al.
2015). Among 111 metabolites there were 39 metabolites which showed a significant change in
normal and G6PDd erythrocytes due to 5, 6-OQPQ treatment. The pathway analysis of these 39
metabolites was done using MetaboAnalyst 3.0, a web application (Figure. 4.9; Table 4.6).
However, among these 39 the metabolites, only those metabolites which showed fold change ≥ 1.2
in normal and G6PDd erythrocytes due to treatment with corresponding time and were considered
a meaningful change.
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In the normal-G6PDd experiment, fold change ≥ 1.5 was used and was considered
meaningful change because in this experiment, the normal and G6PDd erythrocytes were drawn
from different individuals. To make sure that the changes observed were only due to genetic
deficiency and not due to variation in diet or life style, the fold change parameter was increased.
In drug-time-response experiment the normal and G6PDd erythrocytes were drawn from single
individuals thus, the changes observed here are more because of drug-treatment and thus the fold
change ≥ 1.2 is considered meaningful.
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Table 4.4: The metabolites annotated (identified) in normal and G6PDd deficient human
erythrocytes treated with PQ, 5,6-OQPQ (25 µM) in drug-time-response experiment.
HMDB id
HMDB00214
HMDB00062
HMDB05765
HMDB00045
HMDB01325
HMDB04827
HMDB00479
HMDB62709
HMDB00201
HMDB03431
HMDB00064
HMDB00489
HMDB00902
HMDB13127
HMDB00875
HMDB00187
HMDB03640
HMDB13220
HMDB13133
HMDB00824
NA
HMDB00097
HMDB00177
HMDB00086
HMDB01413
HMDB00168
HMDB01202
HMDB00295
HMDB00182
HMDB00961
HMDB03334
HMDB00267
HMDB00043
HMDB01201
HMDB60067
HMDB00251

Metabolite name
Ornithine
L-Carnitine
Ophthalmic acid
Adenosine monophosphate
N6,N6,N6-Trimethyl-L-lysine
Proline betaine
3-Methylhistidine
S-Adenosyl-L-methionine
L-Acetylcarnitine
L-Histidinol
Creatine
Aspartylglycosamine
NAD
Hydroxybutyrylcarnitine
Trigonelline
L-Serine
Beta-Leucine
Beta-Citryl-L-glutamic acid
Methylmalonylcarnitine
Propionylcarnitine
2-Aminomethylpyrimidine
Choline
L-Histidine
Glycerophosphocholine
Citicoline
L-Asparagine
dCMP
Uridine 5'-diphosphate
L-Lysine
Farnesyl pyrophosphate
Symmetric dimethylarginine
Pyroglutamic acid
Betaine
Guanosine diphosphate
CMP-2-aminoethylphosphonate
Taurine
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HMDB01511
HMDB00112
HMDB01539
HMDB00033
HMDB00641
HMDB29198
HMDB00929
HMDB29418
HMDB00191
HMDB00630
HMDB02044
HMDB02249
HMDB00079
HMDB01406
HMDB03337
HMDB00175
HMDB13124
HMDB01341
HMDB00217
HMDB00538
HMDB13131
HMDB32330
HMDB00562
HMDB00939
HMDB02224
HMDB00167
HMDB01125
HMDB00157
HMDB00050
HMDB00510
HMDB60363
HMDB00210
NA
HMDB00159
HMDB06045
HMDB01458
HMDB00696
HMDB05065
HMDB00229
HMDB00687

Phosphocreatine
Gamma-Aminobutyric acid
Asymmetric dimethylarginine
Carnosine
L-Glutamine
Dimethylurea
L-Tryptophan
S-Cysteinosuccinic acid
L-Aspartic acid
Cytosine
8-Hydroxyguanosine
6-Methyltetrahydropterin
Dihydrothymine
Niacinamide
Oxidized glutathione
Inosinic acid
Propenoylcarnitine
ADP
NADP
Adenosine triphosphate
Hydroxyhexanoycarnitine
4-Hydroxy-2-butenoic acid gamma-lactone
Creatinine
S-Adenosylhomocysteine
5-Methyldeoxycytidine
L-Threonine
Inositol cyclic phosphate
Hypoxanthine
Adenosine
Aminoadipic acid
2,5-Dichloro-4-oxohex-2-enedioate
Pantothenic acid
S-(1,2-Dicarboxyethyl) Glutathione
L-Phenylalanine
Dityrosine
Biotin amide
L-Methionine
Oleoylcarnitine
beta-Nicotinamide mononucleotide
L-Leucine
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HMDB00904
HMDB00172
HMDB01173
HMDB00148
HMDB02142
HMDB13854
HMDB10382
HMDB00162
HMDB00222
HMDB01065
HMDB00125
HMDB00034
HMDB00725
HMDB02820
HMDB01545
HMDB00263
HMDB32538
HMDB00517
HMDB00848
HMDB10384
HMDB00158
HMDB31641
HMDB13267
HMDB03045
HMDB00070
HMDB01229
HMDB01066
HMDB13286
HMDB04437
HMDB02117
HMDB13279
HMDB00301
HMDB13648
HMDB29598
HMDB13034

Citrulline
L-Isoleucine
5'-Methylthioadenosine
L-Glutamic acid
Phosphoric acid
N4-Acetylsulfamethoxazole
LysoPC (16:0)
L-Proline
L-Palmitoylcarnitine
Phenyl ethanolamine
Glutathione
Adenine
4-Hydroxyproline
Methylimidazoleacetic acid
Pyridoxal
Phosphoenolpyruvic acid
Triethanolamine
L-Arginine
Stearoylcarnitine
LysoPC (18:0)
L-Tyrosine
Pyrrolidine
N-Decanoylglycine
Ergothioneine
Pipecolic acid
Dopaquinone
S-Lactoylglutathione
N-Undecanoylglycine
Diethanolamine
Oleamide
N-Nonanoylglycine
Urocanic acid
Palmitoleoyl Ethanolamide
Metenamine
Palmitoylglycine
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Table 4.5: Major pathways identified using MetaboAnalyst 3.0 for 111 metabolites annotated in
drug-time-response experiment.
Pathway name
Arginine and proline
Histidine
Glycine, serine and threonine
Alanine, aspartate and glutamate
Glutathione
Glycerophospholipid
Nicotinate and nicotinamide
Purine
Cysteine and methionine

Total
77
44
48
24
38
39
44
92
56
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Hits
12
9
7
5
6
6
6
9
6

-Log (p)
11.54
11.15
6.71
6.70
6.31
6.17
5.54
5.42
4.35

Impact
0.54
0.29
0.25
0.79
0.26
0.08
0.04
0.26
0.20

Figure 4.8: Pathway analysis of 111 metabolites identified in the drug-time-response experiment
using MetaboAnalyst 3.0.
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Table 4.6: Major pathways affected, identified using MetaboAnalyst 3.0 for 39 metabolites
showed significantly changed in normal and G6PDd erythrocytes due to 5,6-OQPQ (25 µM)
treatment as compared to untreated normal and untreated G6PDd erythrocytes with corresponding
time point.
Pathway name
Purine
Glutathione
Arginine and proline
Cysteine and methionine
Glycerophospholipid
Histidine
Alanine, aspartate and glutamate

Total
92
38
77
56
39
44
24

131

Hits
7
4
5
4
3
3
2

-Log (p)
9.04
6.70
5.95
5.26
4.34
4.02
3.29

Impact
0.25
0.24
0.39
0.16
0.05
0.07
0.22

Figure 4.9: Pathway analysis of 39 metabolites showed significantly changed in normal and
G6PDd erythrocytes due to 5,6-OQPQ treatment as compared to untreated normal and untreated
G6PDd erythrocytes with corresponding time point.
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4.5.2.1. Alterations in GSH-methionine-glutamic acid metabolism in normal and G6PDd
erythrocytes due to 5, 6-OQPQ treatment.
The basal level of GSH precursor, DCE-GS (S-1,2-dicarboxyethyl-glutathione) and Slactoylglutathione were significantly increased in G6PDd erythrocytes. DCE-GS was elevated due
to treatment in both erythrocyte groups. However, there was a nonspecific increase of DCE-GS
was in both erythrocytes (Figure 4.10). The basal level of oxidized glutathione and glutamic acid
were significantly lower in G6PDd erythrocytes (Figure 4.10 and 4.11). Oxidized glutathione was
depleted in both erythrocytes at later time points (120 and 480 minutes) due to treatment (Figure
4.10). The level of glutamic acid was depleted selectively in normal erythrocytes due to treatment
at 120 and 480 minutes (Figure 4.11). The level of ophthalmic acid was significantly higher in
both erythrocytes due to treatment at a corresponding time however significant accumulation of
ophthalmic acid was in both erythrocytes due to incubation time (Figure 4.11). There was a
depletion in SAM and 5-methylthioadenosine levels in both erythrocytes due to treatment as
compared to untreated erythrocytes at a corresponding time (Figure 4.12). These results indicate
that metabolites of the GSH-methionine-glutamate pathway were significantly changed in both
erythrocytes due to treatment. The schematic diagram of the GSH-methionine-glutamate pathway
was shown in Figure 4.13.
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Figure 4.10: Distinct effect of 5, 6-OQPQ (25µM) on GSH metabolic pathway and precursors
of GSH in normal and G6PDd erythrocytes at 0, 30, 60, 120, and 480 minutes, and processed with
an untargeted metabolomics workflow. Metabolites were annotated as previously described, and
were mapped onto the GSH metabolic pathways. The levels of metabolites are expressed (Y-axis)
as normalized abundance. Each bar represents mean ± SD of at least three observations. Statistical
differences between groups were determined by ANOVA; P values <0.05 were considered as
statistically significant. *p < 0.05 compared with no treatment with corresponding erythrocytes at
corresponding time. #p < 0.05 compared with pretreatment in normal erythrocyte at 0-minute. 0minute data represent pretreatment erythrocytes. DCE-GS- S-(1,2-Dicarboxyethyl) Glutathione;
GSH- Reduced glutathione; GSSG- Oxidized glutathione.
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Figure 4.11: Distinct effect of 5, 6-OQPQ (25µM) on the glutamic acid metabolic pathway in
normal and G6PDd erythrocytes at 0, 30, 60, 120, and 480 minutes, and processed with an
untargeted metabolomics workflow. Metabolites were annotated as previously described, and were
mapped onto the glutamic metabolic pathways. The levels of metabolites are expressed (y-axis) as
normalized abundance. Each bar represents mean ± SD of at least three observations. Statistical
differences between groups were determined by ANOVA; P values <0.05 were considered as
statistically significant*p < 0.05 compared with no treatment with corresponding erythrocytes at
corresponding time. #p < 0.05 compared with pretreatment in normal erythrocyte at 0-minute. 0minute data represent pretreatment erythrocytes. 0-minute data represent pretreated erythrocytes.
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Figure 4.12. Distinct effect of 5, 6-OQPQ (25µM) on the methionine metabolic pathway in
normal and G6PD-deficient RBCs at 0, 30, 60, 120, and 480 minutes, and processed with an
untargeted metabolomics workflow. Metabolites were annotated as previously described, and were
mapped onto the methionine metabolic pathways. The levels of metabolites are expressed (Y-axis)
as normalized abundance. Each bar represents mean ± SD of at least three observations. Statistical
differences between groups were determined by ANOVA; P values <0.05 were considered as
statistically significant. *p < 0.05 compared with no treatment with corresponding erythrocytes at
corresponding time. 0-minute data represent pretreatment erythrocytes. 0-minute data represent
pretreated erythrocytes. SAH: S-Adenosylhomocysteine; SAM: S-Adenosyl-methionine.
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Figure 4.13: Schematic diagram of glutathione-methionine-glutamic acid metabolism pathway.
The metabolites colored in red, green and purple were identified in normal and G6PDd
erythrocytes treated with 25µM 5, 6-OQPQ for 0, 30, 60, 120, and 480 minutes. Metabolites
colored in black were intermediate of the pathway and were not identified. The metabolites in
purple, red and green showed no change, increase and decrease respectively due to treatment.
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4.5.2.2. Alternations in arginine-proline metabolism in normal and G6PDd erythrocytes due
to 5, 6-OQPQ treatment.
The basal level of proline and arginine were significantly lower and higher in G6PDd
erythrocytes, respectively. The levels of proline, arginine, and ornithine levels were significantly
increased due to treatment in both erythrocytes. However, there was nonspecific depletion of
proline, arginine, and ornithine in both erythrocytes due to incubation (Figure 4.14). These results
suggest the metabolites of arginine-proline were significantly increased due to treatment in normal
and G6PDd erythrocytes.

138

Figure 4.14: Distinct effect of 5, 6-OQPQ (25µM) on the arginine and proline metabolic
pathway in normal and G6PDd erythrocytes at 0, 30, 60, 120, and 480 minutes, and processed with
an untargeted metabolomics workflow. Metabolites were annotated as previously described, and
were mapped onto the arginine and proline metabolic pathways. The levels of metabolites are
expressed (Y-axis) as normalized abundance. Each bar represents mean ± SD of at least three
observations. Statistical differences were determined by ANOVA; P values <0.05 were considered
as statistically significant. *p < 0.05 compared with no treatment with corresponding erythrocytes
at corresponding time. #p < 0.05 compared with pretreatment in normal erythrocyte at 0-minute.
0-minute data represent pretreatment erythrocytes. 0-minute data represent pretreated
erythrocytes.
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4.5.2.3. Alternations in purine and nicotinamide metabolism in normal and G6PDd
erythrocytes due to 5, 6-OQPQ treatment.
There was an accumulation of ADP (adenosine diphosphate) and AMP (adenosine
monophosphate) selectively in normal erythrocytes due to treatment. However, the levels of AMP
were depleted selectively in G6PDd erythrocytes due to treatment. In addition, there was a
nonspecific accumulation of ADP and AMP in both erythrocytes due to incubation. Adenine levels
were significantly depleted in both erythrocytes due to treatment at later time points (120 and 480
minutes) (Figure 4.15). The basal levels of IMP (inosine monophosphate) and GDP (guanosine
diphosphate) were significantly lower and higher in G6PDd erythrocytes respectively. There was
a depletion in IMP and GDP due to treatment in both erythrocytes. Hypoxanthine was accumulated
in both erythrocytes in both erythrocytes due to treatment. There was nonspecific accumulation
and depletion of IMP and hypoxanthine arginine and ornithine in both erythrocytes due to
incubation (Figure 4.16). Furthermore, in the pyrimidine pathway, the NMN (nicotinamide
mononucleotide) levels were significantly depleted in G6PDd erythrocytes due to treatment
(Figure 4.17). These results suggest the metabolites of purine pathway were significantly altered
due to treatment in normal and G6PDd erythrocytes.
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Figure 4.15: Distinct effect of 5, 6-OQPQ (25µM) on the purine (ATP and its precursor)
metabolic pathway in normal and G6PDd erythrocytes at 0, 30, 60, 120, and 480 minutes, and
processed with an untargeted metabolomics workflow. Metabolites were annotated as previously
described, and were mapped onto the purine metabolic pathways. The levels of metabolites are
expressed (-axis) as normalized abundance. Each bar represents mean ± SD of at least three
observations. Statistical differences were determined by ANOVA; P values <0.05 were considered
as statistically significant. *p < 0.05 compared with no treatment with corresponding erythrocytes
at corresponding time. #p < 0.05 compared with pretreatment in normal erythrocyte at 0-minute.
0-minute data represent pretreatment erythrocytes. ATP: Adenosine triphosphate. ADP:
Adenosine diphosphate. AMP: Adenosine monophosphate.
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Figure 4.16: Distinct effect of 5, 6-OQPQ (25µM) on the purine (IMP, hypoxanthine, and GDP)
metabolic pathway in normal and G6PDd erythrocytes at 0, 30, 60, 120, and 480 minutes, and
processed with an untargeted metabolomics workflow. Metabolites were annotated as previously
described, and were mapped onto the purine metabolic pathways. The levels of metabolites are
expressed (Y-axis) as normalized abundance. Each bar represents mean ± SD of at least three
observations. Statistical differences were determined by ANOVA; P values <0.05 were considered
as statistically significant. *p < 0.05 compared with no treatment with corresponding erythrocytes
at corresponding time. #p < 0.05 compared with pretreatment in normal erythrocyte at 0-minute.
0-minute data represent pretreatment erythrocytes. IMP: Inosine monophosphate. GDP:
Guanosine diphosphate.

142

Figure 4.17: Distinct effect of 5, 6-OQPQ (25µM) on the NMN levels in normal and G6PDd
erythrocytes at 0, 30, 60, 120, and 480 minutes, and processed with an untargeted metabolomics
workflow. Metabolites were annotated as previously described. The levels of metabolites are
expressed (Y-axis) as normalized abundance. Each bar represents mean ± SD of at least three
observations. Statistical differences between 5, 6-OQPQ-treated normal and G6PD-deficient cells
were determined by ANOVA; P values <0.05 were considered as statistically significant. *p < 0.05
compared with no treatment with corresponding erythrocytes at corresponding time. 0-minute data
represent pretreatment erythrocytes. 0-minute data represent pretreated erythrocytes. NMN:
Nicotinamide mononucleotide.
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4.5.2.4. Alternations in glycerophospholipid metabolism in normal and G6PDd erythrocytes
due to 5, 6-OQPQ treatment.
The basal levels of GPC (glycerophosphocholine), lysophosphatidylcholines (LPC) (16:0)
and lysophosphatidylcholines (18:0) were significantly lower in G6PDd erythrocytes (Figure
4.18). GPC levels were elevated in normal and G6PDd erythrocytes due to treatment. LPC (16:0)
and LPC (18:0) were depleted at 120 minutes in both normal and G6PDd erythrocytes and were
increased selectively in G6PDd erythrocytes at 480 minutes due to treatment (Figure 4.18).
Citicoline, a biomarker of chronic hemolysis and formed from phosphocholine (Paglia et al. 1983)
was selectively accumulated in G6PDd erythrocytes due to treatment at all time points (Figure
4.18). These results indicate the metabolites of glycerophospholipid pathway were significantly
modified due to treatment in normal and G6PDd erythrocytes.
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Figure 4.18: Distinct effect of 5, 6-OQPQ (25µM) on the glycerophospholipid metabolic
pathway in normal and G6PDd erythrocytes at 0, 30, 60, 120, and 480 minutes, and processed with
an untargeted metabolomics workflow. Metabolites were annotated as previously described, and
were mapped onto the glycerophospholipid metabolic pathways. The levels of metabolites are
expressed (Y-axis) as normalized abundance. Each bar represents mean ± SD of at least three
observations. Statistical differences were determined by ANOVA; P values <0.05 were considered
as statistically significant. *p < 0.05 compared with no treatment with corresponding erythrocytes
at corresponding time. #p < 0.05 compared with pretreatment in normal erythrocyte at 0-minute.
0-minute data represent pretreatment erythrocytes. GPC: Glycerophosphocholine; LPC (16:0):
Lysophosphatidylcholines (16:0); LPC (18:0): Lysophosphatidylcholines (18:0).
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4.5.2.5. Alternations in histidine metabolism in normal and G6PDd erythrocytes due to 5, 6OQPQ treatment.
The basal level of ergothioneine, the natural metabolite of histidine metabolism and
antioxidant was increased in G6PDd erythrocytes (Halliwell et al. 2016). The level of histidinol,
the precursor of histidine and ergothioneine both were significantly higher in both erythrocytes
due to treatment (Figure 4.19). These results showed that the precursor and metabolites of histidine
were significantly elevated in erythrocytes due to treatment.

4.5.2.6. Alternations in antioxidants in normal and G6PDd erythrocytes due to 5, 6-OQPQ
treatment.
The basal levels of antioxidant pantothenic acid and BCGA (beta-citryl-glutamic

acid)

were elevated in G6PDd erythrocytes and serine was depleted in G6PDd erythrocytes (Figure
4.20). Treatment elevated lysine, BCGA, and serine in both erythrocytes at later time point (120
and 480 minutes) suggesting that in response to treatment the antioxidant levels were increased as
a compensatory mechanism. However, the levels of pantothenic acid were depleted selectively in
G6PDd erythrocytes due to treatment (Figure 4.20). These results showed that treatment elevated
antioxidants in both erythrocytes as a compensatory mechanism.
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Figure 4.19: Distinct effect of 5, 6-OQPQ (25µM) on the histidine metabolic pathway in normal
and G6PDd erythrocytes at 0, 30, 60, 120, and 480 minutes, and processed with an untargeted
metabolomics workflow. Metabolites were annotated as previously described, and were mapped
onto the histidine metabolic pathways. The levels of metabolites are expressed (Y-axis) as
normalized abundance. Each bar represents mean ± SD of at least three observations. Statistical
differences were determined by ANOVA; P values <0.05 were considered as statistically
significant*p < 0.05 compared with no treatment with corresponding erythrocytes at corresponding
time. #p < 0.05 compared with pretreatment in normal erythrocyte at 0-minute. 0-minute data
represent pretreatment erythrocytes. 0-minute data represent pretreated erythrocytes.
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Figure 4.20: Distinct effect of 5, 6-OQPQ (25µM) on the antioxidants namely, lysine,
pantothenic acid, BCGA (beta-citryl-glutamic acid) and serine levels in normal and G6PDd
erythrocytes at 0, 30, 60, 120, and 480 minutes, and analyzed for their metabolite profiles. The
levels of metabolites are expressed (Y-axis) as normalized abundance. Each bar represents mean
± SD of at least three observations. Statistical differences were determined by ANOVA; P values
<0.05 were considered as statistically significant. *p < 0.05 compared with no treatment with
corresponding erythrocytes at corresponding time. #p < 0.05 compared with pretreatment in normal
erythrocyte at 0-minute. 0-minute data represent pretreatment erythrocytes. 0-minute data
represent pretreatment erythrocytes. 0-minute data represent pretreated erythrocytes.
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4.5.2.7. Alternations in hemolysis and oxidative stress biomarkers in normal and G6PDd
erythrocytes due to 5, 6-OQPQ treatment.
The basal levels of SDMA (symmetric dimethylarginine) and dityrosine were elevated in
G6PDd erythrocytes, and ADMA (asymmetric dimethylarginine) was depleted in G6PDd
erythrocytes (Figure 4.21). SDMA and ADMA were elevated due to treatment. SMDA selectively
accumulated in G6PDd erythrocytes and ADMA was accumulated in both erythrocytes due to
treatment. There was nonspecific depletion of SDMA and ADMA in both erythrocytes due to
incubation. Dityrosine and dopaquinone were depleted in both erythrocytes due to treatment. There
was the nonspecific elevation of dopaquinone in both erythrocytes due to incubation (Figure 4.21).
These results showed that treatment affects hemolysis, oxidative stress and aging biomarker in
both erythrocytes.

4.5.2.8. Alternations in MTH, MTC, leucine, and phosphocreatine in normal and G6PDd
erythrocytes due to 5, 6-OQPQ treatment.
The basal levels of MDC (5-methyldeoxycitidine) and phosphocreatine were elevated in
G6PDd erythrocytes, and leucine was depleted in G6PDd erythrocytes (Figure 4.22). Treatment
elevated levels of MDC and phosphocreatine and leucine in both erythrocytes. Levels of
phosphocreatine were selectively increased in G6PDd erythrocytes. Treatment decreased MDC
levels in both erythrocytes. There was a non-specific decrease in leucine in both erythrocytes due
to incubation (Figure 4.22).

149

Figure 4.21. Distinct effect of 5, 6-OQPQ (25 µM) on SDMA, ADMA, dityrosine and
dopaquinone levels in normal and G6PDd erythrocytes at 0, 30, 60, 120, and 480 minutes, and
analyzed for their metabolite profiles. The levels of metabolites are expressed (Y-axis) as
normalized abundance. Each bar represents mean ± SD of at least three observations. Statistical
differences were determined by ANOVA; P values <0.05 were considered as statistically
significant. *p < 0.05 compared with no treatment with corresponding erythrocytes at
corresponding time. #p < 0.05 compared with pretreatment in normal erythrocyte at 0-minute. 0minute data represent pretreatment erythrocytes. 0-minute data represent pretreatment
erythrocytes.0-minute data represent pretreated erythrocytes. SMDA: Symmetric
dimethylarginine. ADMA: Asymmetric dimethylarginine.
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Figure 4.22: Distinct effect of 5, 6-OQPQ (25µM) on the MTH, MDC, leucine and
phosphocreatine levels in normal and G6PDd erythrocytes at 0, 30, 60, 120, and 480 minutes,
and analyzed for their metabolite profiles. The levels of metabolites are expressed (Y-axis) as
normalized abundance. Each bar represents mean ± SD of at least three observations. Statistical
differences were determined by ANOVA; P values <0.05 were considered as statistically
significant*p < 0.05 compared with no treatment with corresponding erythrocytes at corresponding
time. #p < 0.05 compared with pretreatment in normal erythrocyte at 0-minute. 0-minute data
represent pretreatment erythrocytes. 0-minute data represent pretreatment erythrocytes.0-minute
data represent pretreated erythrocytes. MTH: 6-methyltetrahydropterin. MDC: 5methyldeoxycytidine.
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4.5.3. Common metabolites in normal-G6PDd experiment and drug-time-response
experiment.
There were 66 metabolites which were commonly identified in both experiments. The
detail of these metabolites with their normalized abundance was described in Table 4.7 and Table
4.8.
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Table 4.7: Lists of common metabolites annotated and their normalized abundance (Mean and
SD) in normal erythrocytes in both normal-G6PDd experiment and drug-time-response
experiment.
Normal-G6PDd experiment

Description
2,5-Dichloro-4-oxohex
-2-enedioate
3-Methylhistidine
4-Hydroxy-2-butenoic acid
gamma-lactone
5'-Methylthioadenosine
Adenine
Adenosine monophosphate
ADP
Betaine
Biotin amide
Choline
Citrulline
CMP-2aminoethylphosphonate
Creatine
Creatinine
Ergothioneine
Farnesyl pyrophosphate
Gamma-Aminobutyric acid
Glutathione
Glycerophosphocholine
Hydroxybutyrylcarnitine
Hypoxanthine
Inosinic acid
L-Acetylcarnitine
L-Arginine
L-Asparagine
L-Aspartic acid
L-Carnitine
L-Glutamic acid
L-Glutamine
L-Histidine

Normal erythrocytes
Mean
SD
6298179.24
1656459.59

Drug-time-response
experiment
Normal erythrocytes
Mean
SD
7245169.17
182649.31

1753733.62
25642.31

1384796.28
9832.45

3948042.73
8218.88

180334.33
325.28

329056.15
19622.43
323028.04
508146.89
9854665.06
23259.56
7651067.75
1100310.44
85183.85

113843.19
3235.87
201345.04
185127.15
1885975.93
11741.25
4674310.49
257547.15
28629.68

496687.04
97089.07
265135.48
6251585.95
13630389.61
46354.69
7209640.73
1838015.72
228284.68

19056.17
5978.72
7599.72
441201.68
144364.07
3143.65
82413.45
135396.53
29300.48

28659415.84
4750868.75
19394.73
448115.63
43100.63
125006.72
156883.04
293870.74
1239929.47
206291.19
19382135.22
533239.62
312131.26
161911.30
8695931.51
659687.48
1960260.06
238275.12

1621178.31
654875.19
16446.25
222499.17
5042.56
149046.12
95245.52
153593.81
567572.48
64272.42
7017580.19
220127.71
62672.68
98611.55
3725851.54
308042.27
464758.90
54713.43

3794777.46
5927286.76
496498.76
221300.86
97243.91
1300921.29
1546687.16
85144.68
32164.54
3077085.13
983742.98
8726580.48
709759.86
529903.46
1194144.18
13866888.96
2290404.87
1316890.00

96843.13
320104.43
238150.14
34919.04
1851.78
1437512.01
281379.69
4843.33
441.71
189833.95
100682.97
203735.26
138856.18
26427.06
37337.59
591662.79
75011.39
92776.33
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L-Histidinol
L-Isoleucine
L-Leucine
L-Methionine
L-Norleucine
L-Palmitoylcarnitine
L-Phenylalanine
L-Proline
L-Serine
L-Threonine
L-Tryptophan
L-Tyrosine
LysoPC(16:0)
LysoPC(18:0)
Methylmalonylcarnitine
N6,N6,N6-Trimethyl-Llysine
NAD
N-Decanoylglycine
Niacinamide
N-Undecanoylglycine
Oleoylcarnitine
Ophthalmic acid
Ornithine
Oxidized glutathione
Pantothenic acid
Phosphocreatine
Phosphoric acid
Pipecolic acid
Proline betaine
Propionylcarnitine
Pyroglutamic acid
Pyrrolidine
Stearoylcarnitine
Taurine
Trigonelline
Uridine 5'-diphosphate

1397574.40
371135.47
421042.54
56142.99
120161.11
1749789.01
386616.80
2034823.75
85725.77
233988.78
91950.97
257470.70
9486034.38
6216279.52
1192570.70
2269710.97

220727.26
148837.84
161682.29
21370.53
76380.11
793668.47
105705.49
278503.60
9614.63
28823.87
28817.73
102429.84
2830304.04
1978632.16
443762.38
439161.40

10738833.53
30319.23
835375.28
1015899.57
351802.04
209141.10
680230.67
3871337.20
59153.45
259938.71
312095.48
924326.87
1302394.23
712508.48
3194952.66
1956589.06

271379.36
1421.20
26393.87
31817.46
43471.56
64820.65
45358.84
96310.16
3300.20
8920.35
24446.90
100488.95
111652.79
214629.73
335370.61
182540.22

1651753.14
36969.16
708690.92
354588.37
3311751.41
86278.81
488951.99
16500582.81
84864.84
24083.34
6554.04
358495.03
7684600.13
3791068.47
569409.76
51841.72
1024579.87
231738.77
180387.49
69506.67

273296.52
8185.04
237915.26
98940.10
1366332.93
16946.20
61149.36
4649985.88
81933.74
12301.67
3652.96
615310.98
6487641.04
1988628.24
132703.94
7925.69
435731.70
142558.67
83212.35
17467.74

3571121.70
259693.71
569419.44
1357004.19
238627.04
114041.52
6306402.07
74975807.89
542893.97
29944.26
25247.93
192634.83
2065.59
5201753.34
402319.93
125610.72
192367.58
74403.01
411590.89
81930.23

553902.16
21806.22
59813.45
213753.25
162102.44
9521.48
166234.33
10812731.40
24883.64
3073.47
958.86
24032.17
56.99
141751.18
23365.39
6634.00
36543.47
1873.79
16623.84
9207.47
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Table 4.8: Lists of common metabolites annotated and their normalized abundance (Mean and
SD) in G6PDd erythrocytes in both normal -G6PDd experiment and drug-time-response
experiment.
Normal-G6PDd experiment

Description
2,5-Dichloro-4oxohex-2-enedioate
3-Methylhistidine
4-Hydroxy-2-butenoic acid
gamma-lactone
5'-Methylthioadenosine
Adenine
Adenosine monophosphate
ADP
Betaine
Biotin amide
Choline
Citrulline
CMP-2-aminoethylphosphonate
Creatine
Creatinine
Ergothioneine
Farnesyl pyrophosphate
Gamma-Aminobutyric acid
Glutathione
Glycerophosphocholine
Hydroxybutyrylcarnitine
Hypoxanthine
Inosinic acid
L-Acetylcarnitine
L-Arginine
L-Asparagine
L-Aspartic acid
L-Carnitine
L-Glutamic acid
L-Glutamine
L-Histidine
L-Histidinol

G6PDd erythrocytes
Mean
SD
6012686.70 1031473.33

Drug-time-response
experiment
G6PDd erythrocytes
Mean
SD
7371153.31
193531.88

2188241.97
29555.50

1156990.24
4709.64

4873143.67
12488.81

242237.33
361.42

508191.62
18154.64
123400.08
344986.02
10641366.83
54683.89
3766634.26
1173147.68
116891.47
26272575.53
4485204.43
11405.99
435064.96
44774.88
18358.39
115337.55
703192.14
2257187.69
209186.94
21877132.97
706584.27
197779.25
279244.69
11261154.29
256424.32
1838946.30
195084.76
1112566.12

166106.38
2560.71
122174.01
212749.52
254947.72
21769.14
2162376.67
231361.76
21765.10
1443005.23
288770.24
4879.09
68081.68
6959.44
7455.32
76257.86
268473.47
1328444.08
130924.29
3250112.04
418116.83
70678.92
113722.11
887933.15
227227.88
396593.71
53015.50
162627.25

493566.99
98010.74
868679.74
8096303.80
14282662.76
266174.56
3270526.40
1554602.18
234943.82
5028598.27
7785782.44
1305595.50
911107.34
160266.65
306722.77
816714.67
452286.21
69256.37
2942326.05
516313.07
12832427.97
1465400.08
331958.51
271900.82
13555246.99
839911.76
1022795.23
10164007.88

43573.48
2608.14
67304.35
1237492.03
462268.05
23594.82
71793.85
48458.02
22384.23
130976.01
391986.21
245722.26
88176.40
6295.54
134150.23
73415.76
9720.61
3842.35
236036.33
50453.82
453395.32
69583.77
11017.02
7077.86
290003.92
69843.26
47449.71
394111.02
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L-Isoleucine
L-Leucine
L-Methionine
L-Norleucine
L-Palmitoylcarnitine
L-Phenylalanine
L-Proline
L-Serine
L-Threonine
L-Tryptophan
L-Tyrosine
LysoPC(16:0)
LysoPC(18:0)
Methylmalonylcarnitine
N6,N6,N6-TrimethylL-lysine
NAD
N-Decanoylglycine
Niacinamide
N-Undecanoylglycine
Oleoylcarnitine
Ophthalmic acid
Ornithine
Oxidized glutathione
Pantothenic acid
Phosphocreatine
Phosphoric acid
Pipecolic acid
Proline betaine
Propionylcarnitine
Pyroglutamic acid
Pyrrolidine
Stearoylcarnitine
Taurine
Trigonelline
Uridine 5'-diphosphate

517775.87
652760.21
44020.19
220663.94
2029483.36
444826.15
2018391.64
67302.72
216999.93
90833.98
210335.12
6033925.34
4176371.31
1421867.51
2402360.68

180949.63
200667.91
7544.24
180247.31
507592.36
120467.14
148321.90
25354.05
75452.05
19872.68
23318.11
2424153.21
1772720.69
710599.56
597307.22

30580.17
783227.80
887918.24
369264.15
136064.23
570330.99
3347829.78
45310.99
220117.10
253396.46
925047.09
497628.24
220413.41
2266440.88
2686557.80

1842.49
39474.25
37725.01
52420.63
76632.17
22367.79
43872.48
801.17
13871.15
9696.50
41715.07
150042.67
30508.68
105833.55
127204.35

2112321.73
21110.31
1009133.24
205205.33
4126495.84
36398.82
413922.32
11613412.28
111824.97
31595.71
7383.75
69924.58
6355894.24
6302821.18
532726.01
65963.69
1991111.83
137975.86
495849.31
67501.26

356485.66
11043.21
113092.47
98666.06
1066355.15
23198.93
63885.86
4595472.91
35910.25
12597.51
5920.08
98177.03
8003257.93
924522.51
113901.62
11132.50
541859.71
48447.48
396151.55
16004.26

5644409.44
181709.41
1084718.71
1073334.59
311001.40
94091.23
6443207.49
49992603.19
787547.29
50346.09
28058.76
131134.47
124321.43
4976433.48
332322.57
118775.30
93155.39
73288.11
608417.08
143336.84

269867.18
60227.82
71034.64
358864.03
190306.57
2085.54
130052.89
1949433.14
15169.15
2195.77
474.55
21772.37
2345.49
110502.07
10233.05
5934.49
38869.35
452.96
15475.09
9870.28
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4.6. DISCUSSION
G6PD deficiency is an X-linked hereditary disorder caused due to a mutation in G6PD
gene (Cappellini and Fiorelli 2008; Youngster et al. 2010). G6PD enzyme participates in the
pentose phosphate pathway, which is the sole source for production of NADPH, glutathione
recycling in erythrocytes, and is essential for the function of catalase (Nkhoma et al. 2009; Mason
et al. 2007; Cappellini and Fiorelli 2008; Judith Recht 2014). NADPH, GSH, and catalase
constitute primary antioxidant defense system in human erythrocytes (Judith Recht 2014). The
G6PDd erythrocytes have limited capability to regenerate NADPH and recycle GSH and thus,
have lower levels of GSH (Judith Recht 2014; Mason et al. 2007). The results of the current study
are consistent with the earlier reports and thus support the known data (Nkhoma et al. 2009; Mason
et al. 2007; Cappellini and Fiorelli 2008; Judith Recht 2014).
In this study, the basal normal and G6PDd metabolome profiles were compared to identify
the major pathways which were modified in G6PDd erythrocytes. The comparison between
metabolites in normal and G6PDd revealed that GSH levels were significantly lower in G6PDd
erythrocytes. The GSH-Methionine-Glutamate pathway was interconnected and together
participate in GSH synthesis (Tang et al. 2015). In our study, the levels of GSH, tripeptide analog
of ophthalmic acid and glutamic acid, the precursor of GSH were significantly lower in G6PDd
erythrocyte. Furthermore, 5'-methylthioadenosine which plays a crucial role in methionine and
purine salvage pathways (Avila et al. 2004) were higher. Moreover, the metabolites participate in
glycerophospholipid pathway like choline, neurine and LysoPC (16:0) were lower (Gibellini and
Smith 2010; Tweedie et al. 2006; Saito et al. 2014). Carnitine and derivatives of carnitine
participate were higher and in lipid oxidation (Darghouth et al. 2011), and the metabolite of fatty
acid namely, N-decanoylglycine and N-undecanoylglycine were significantly lower (Cruickshank157

Quinn et al. 2014). These findings suggest disruption of lipid/fatty acid oxidation and
glycerophospholipid pathway. The glycerophospholipids phosphatidylcholine play major roles in
the structure and function of those eukaryotic membranes (Gibellini and Smith 2010), and the
disruption of lipid oxidation and glycerophospholipid pathway might indicate the membrane
fragility seen in G6PDd erythrocytes (Johnson et al. 1994).
Another focus of the current study was to examine the metabolomes of both normal and
G6PDd erythrocytes treated with a hemotoxic metabolite of PQ, 5,6-OQPQ for 30, 60, 120 and
480 minutes. The results showed that the GSH-methionine-glutamic acid pathway was highly
affected due to treatment in both erythrocytes. Oxidized glutathione and precursors of GSH
namely, glutamic acid (Ellinger et al. 2011), 5-methylthioadenosine, and SAM were depleted at
later time points (120 and 480 minutes) of treatment in both erythrocytes. Similarly, adenine the
precursor of ATP was also depleted at later time points in both erythrocytes. However, the level
of serine, BCGA and lysine were considerably increased due to treatment in both erythrocytes at
120 and 480 minutes. Serine plays an important role in providing one-carbon units to the
tetrahydrofolate (THF) cycle and supports ATP and NADPH generation. ATP generates by serine
is used by methionine to form S-adenosyl methionine (SAM) (Maddocks et al. 2016). In addition,
serine has antioxidant properties and it protects the cells from H 2O2-induced oxidative stress
(Miyazaki et al. 1992). BCGA is a derivative of glutamic acid and acts as metal ion chelator.
BCGA also has antioxidant activity like the enzyme super oxide dismutase (Hamada-Kanazawa et
al. 2010; Narahara et al. 2010). Like serine and BCGA, lysine also has antioxidant activities
(O'Doherty et al. 2014). The change in these metabolites at 120 and 480 minutes indicates the
compensatory mechanism of erythrocyte and suggest that it is almost similar in both erythrocytes.
The level of ophthalmic acid, a tripeptide analog of GSH was increased due to treatment
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in both erythrocytes at early and later time points. Ophthalmic acid was formed from 2aminobutyrate via consecutive reactions with gamma-glutamylcysteine and glutathione synthetase
like glutathione formation. GSH contain a thiol group from cysteine in GSH and in ophthalmic
acid the thiol group is replaced by a methyl group. The enzyme gamma-glutamylcysteine
synthetase, is feedback-inhibited by GSH, and is considered as a rate-limiting step in GSH
formation (Cuozzo and Kaiser 1999). GSH depletion caused by oxidative compounds like
acetaminophen activates gamma-glutamylcysteine synthetase, which in turn induced ophthalmic
acid formation. Though, unlike GSH, ophthalmic acid is not metabolized further and thus is
accumulated (Soga et al. 2006).
The levels of citicoline, SDMA and phosphocreatine were higher selectively in G6PDd
erythrocytes due to 5,6-OQPQ treatment. Phosphocreatine decreases oxidative stress (Cunha et al.
2014) and furthermore, it interacts with membrane lipids and causes modifications in membrane
structure in order to protect cellular membranes against different insults (Tokarska-Schlattner et
al. 2012). Citicoline is a biomarker of chronic hemolysis (Paglia et al. 1983). SDMA is proinflammatory and pro-oxidant in nature (Tain and Hsu 2017) and is related with oxidative stress
induction (Schepers et al. 2011). Higher SDMA levels have been reported in numerous clinical
conditions like coronary artery disease, diabetes mellitus, hypertension, hyperuricemia,
preeclampsia, polycystic ovary syndrome, and stroke (Tain and Hsu 2017). ADMA levels were
also elevated but in both erythrocytes and at later time points. Elevated ADMA levels are
associated with genetic disease-related with hemolysis like sickle cell disease, thalassemia and
other complications related with hemolysis like leg ulcers, cholelithiasis, and priapism (Landburg
et al. 2010).
Treatment of 5,6-OQPQ elevated levels of proline and ornithine. Proline defends the cells
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against hydrogen peroxide-induced stress and accumulation of proline is a compensatory response
of hydrogen peroxide-induced stress. Moreover, proline takes care the intracellular GSH pool and
the GSH/GSSG ratio of the cell during oxidative stress (Krishnan et al. 2008). Ornithine is a
biomarker of hemolysis. During hemolysis, erythrocytes release red-cell arginase, an enzyme
cause conversion of arginine to ornithine (Morris et al. 2005).
Thus, the current study suggests that histidine, GSH-Methionine-Glutamate, purine,
glycerophospholipid and fatty acid oxidation pathways were greatly affected in G6PDd
erythrocytes as compare to normal erythrocyte. Moreover, treatment of 5,6-OQPQ, a metabolite
of PQ significantly modified GSH-methionine-glutamic acid, histidine and glycerophospholipid
pathway. Furthermore, the metabolites changed at later time points suggest compensatory
mechanism. The level of antioxidant like serine, lysine and BCGA were elevated in both
erythrocytes due to 5,6-OQPQ treatment at later time points. Hemolysis related markers like
citicoline and SDMA were also elevated selectively in G6PDd erythrocytes due to 5,6-OQPQ
treatment which can be used as new hemotoxic marker related with PQ-induced.
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CHAPTER 5
FUTURE STUDIES

8-aminoquinolines (8-AQs) represent an important drug class with unique antiprotozoal
activities. 8-AQs are used in the treatment of leishmaniasis, pneumocystis infections,
trypanosomiasis and malaria (Tekwani and Walker 2006). Primaquine (PQ) is a unique 8-AQ
antimalarial drug. It is the only FDA-approved drug, which is active against the hard-to-kill liver
stage of Plasmodium vivax and P. ovale and used to prevent malaria relapse (Ashley et al. 2014;
Tekwani and Walker 2006). Malaria relapses significantly contribute to infection and morbidity in
P. vivax and P. ovale malaria (Leslie et al. 2016). Further, PQ is the only drug having activity
against mature stage V gametocytes of P. falciparum and thus recommended by the World Health
Organization, to prevent malaria transmission (Tekwani and Walker 2006; Ashley et al. 2014).
The current in vitro studies showed that the metabolites of PQ namely, 5-HPQ, 5,6-OQPQ,
and MHQ are hemotoxic and induce a concentration-dependent hemotoxicity response by
generating methemoglobinemia and producing oxidative stress in normal and G6PDd human
erythrocytes. The PQ metabolite 5,6-OQPQ also depletes GSH and induces the exposure of
phosphatidylserine (a marker for suicidal erythrocyte death-eryptosis) on the outer membrane of
erythrocytes, selectively in G6PDd human erythrocytes. Externalization of PS on the outer
membrane is the final commitment of erythrocyte to be phagocytized by macrophages. The
eryptotic pathway triggers the removal of damaged erythrocytes from the circulation in the G6PDd
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population on exposure to PQ. Further, other biochemical and cellular markers associated with
eryptosis namely, intraerythrocytic calcium levels and activation of calpain can also be evaluated
to gain a better insight into the pathways and events that lead to hemolysis caused by PQ.
The role of NQO2, a cytosolic flavoprotein enzyme involved in metabolic
detoxification/activation of quinones, in PQ-induced hemolytic anemia was also investigated. To
acheieve this, the inhibitors of NQO2 namely, melatonin (Mel), resveratrol (Res) and quercetin
(Quer) were used as the probes. The interactions between human NQO2 (PBD: 4FGJ) and PQ
metabolites (5-HPQ, 5,6-OQPQ, and MHQ) were also investigated using molecular docking
approach. The results of the current study suggest that co-treatment of erythrocytes with NQO2
inhibitors and PQ metabolites potentiated the hemotoxicity compared to PQ metabolites alone.
These results suggest potential role of NQO2 in detoxification of reactive metabolites of PQ and
protection of erythrocytes from PQ-induced hemolysis. The computational docking results suggest
that Mel, menadione, PQ and PQ metabolites bind at the same binding pocket of the NQO2 with
a slightly different orientations; however, the glide gscores results suggest that PQ and its
metabolites may have a better affinity towards NQO2 as compared to Mel and menadione.
Additional experiments may be done to understand the functional interactions (substrate or
inhibitor) of PQ metabolites with human NQO2.
Finally, the changes in metabolite levels and biochemical pathways in normal and G6PDd
erythrocytes due to 5,6-OQPQ treatments were examined. A battery of metabolites (citicoline,
SDMA and phosphocreatine) are selectively changed in the G6PDd erythrocytes. These
metabolites can be evaluated as the markers of PQ-induced hemolysis. Changes in some
metabolites like serine, BCGA, lysine, glutamic acid suggest compensatory mechanism of PQ162

induced toxicity in normal and G6PDd erythrocytes. The knowledge regarding compensatory
mechanisms can be used to formulate the strategy for attenuation of PQ-induced toxicity, without
compromising with the therapeutic activity
The study provides a better insight into the pathways and biomarkers of toxicity involved
with the PQ-treatment. Further, the knowledge regarding the interaction of PQ metabolites with
NQO2 enzyme is clearer now and suggests the potential target related to the PQ-toxicity. In
summary, the data obtained in this study provide the knowledge to understand the mechanism,
pathway and target associated with PQ toxicity and would help to improved therapeutic value of
PQ. Also, the knowledge generated through proposed studies will allow multiple avenues of
development of 8-AQ analogs with improved safety and therapeutic profiles for malaria control
and elimination campaigns.
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(District level children science festival), District Science Club, Jhansi, India.

2002:

2nd place in Environmental Management Model in Regional Science Exhibition,
Jhansi, India.

2002-2003:

Ekikrat Scholarship of Uttar Pradesh government for two years.

Professional Societies and Committee Responsibilities:
2016-2017:

Senate (Pharmacology Division, Department of BioMolecular Sciences), Graduate
Student Council, University of Mississippi.

2016-2017:

Secretary in Public Relation, Indian Student Association (ISA), University of
Mississippi.

2015:

Phi Kappa Phi Honor Society

2015:

American Association of Pharmaceutical Scientists (AAPS)

2015:

Golden Key International Honor Society

2015:

American Society of Tropical Medicine & Hygiene (ASTMH) Society

2015-2016:

Vice President, Indian Student Association (ISA), University of Mississippi.
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Published Abstracts:
1. Metabolic conversion of carboxy-primaquine, a major metabolite of primaquine, to
potential hemotoxic intermediates. Jagrati Jain, Narayan D Chaurasiya, Bharathi Avula,
NP Dhammika Nanayakkara, James D McChesney, Ikhlas A. Khan, Larry A Walker and
Babu L Tekwani. Abstract Number 850. 65th Annual Meeting, American Society of
Tropical Medicine & Hygiene (ASTMH), 2016.
2. Quercetin potentiates the toxicity of hemolytic drugs in G6PD deficient human
erythrocytes. Jagrati Jain, Narayan D Chaurasiya, NP Dhammika Nanayakkara, James D
McChesney, Larry A Walker and Babu L Tekwani. Planta Med 2016; 82 - PB17
3. NRH: Quinone Reductase 2 (NQO2) Protects Against Hemolytic Toxicity Induced by
Primaquine Antimalarial in G6PD Deficient Human Erythrocytes. Jagrati Jain,
Narayan D Chaurasiya, NP Dhammika Nanayakkara, James D McChesney, Larry A
Walker and Babu L Tekwani. Abstract Number 970. 64th Annual Meeting, American
Society of Tropical Medicine & Hygiene (ASTMH), 2015.
4. Effect of Quinone Reductase 2 (NQO2) Inhibitor Melatonin on Primaquine-Induced
Hemolysis. J Jain, ND Chaurasiya, R Sahu, NP Dhammika Nanayakkara, LA Walker, BL
Tekwani. Planta Med 2015; 81 - PP4. DOI: 10.1055/s-0035-1545221.
5. Inhibitors of ubiquitin E3 ligase as potential new antimalarial drug leads. Jagrati Jain,
Rajnish Sahu, Larry A Walker, Babu L Tekwani. Abstract Number 295. 63rd Annual
Meeting, American Society of Tropical Medicine & Hygiene (ASTMH), 2014.
Published Research Paper:
1. Ubiquitin E3 ligase inhibitors’ as potential new antimalarial drug leads. Jain J, Jain SK,
Walker LA, Tekwani BL. BMC Pharmacol Toxicol. 2017 Jun 2;18(1):40.
Pending Research Papers:
1. Quercetin potentiates hemotoxic effect of hemolytic drugs in human erythrocytes. (Draft
given to advisor).
2. Protective role of Quinone Reductase 2 (NQO2) in primaquine-induced hemotoxicity in
human erythrocytes. (Tentative title).
3. Metabolome changes in normal and G6PD deficient human erythrocytes in response to
primaquine metabolite. (Tentative title).
4. Drug-induced oxidative hemolysis (review)
Poster Presentations:
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1. Metabolic conversion of carboxy-primaquine, a major metabolite of primaquine, to
potential hemotoxic intermediates. Jagrati Jain, Narayan D Chaurasiya, Bharathi Avula,
NP Dhammika Nanayakkara, James D McChesney, Ikhlas A. Khan, Larry A Walker and
Babu L Tekwani. Abstract Number 850. 65th Annual Meeting, American Society of
Tropical Medicine & Hygiene (ASTMH), 2016.
2. Hemolytic Drug Metabolites Produce Eryptotic Response in G6PD Deficient Human
Erythrocytes. Jagrati Jain, Narayan D Chaurasiya, Bharathi Avula, NP Dhammika
Nanayakkara, James D McChesney, Larry A Walker and Babu L Tekwani. 4 th Malaria
Symposium. April 25th, 2016.
3. Metabolism and Toxicity of Carboxy-Primaquine, the Major Plasma Metabolite of
Primaquine. Jagrati Jain, Narayan D Chaurasiya, Bharathi Avula, NP Dhammika
Nanayakkara, James D McChesney, Larry A Walker and Babu L Tekwani. 4 th Malaria
Symposium. April 25th, 2016.
4. Quercetin potentiates eryptotic response of hemolytic drugs in G6PD deficient
human erythrocytes. Jagrati Jain, Narayan D Chaurasiya, NP Dhammika Nanayakkara,
James D McChesney, Larry A Walker and Babu L Tekwani. 6th Graduate Student
Council Symposium. April 15th, 2016.
5. Quercetin potentiates the toxicity of hemolytic drugs in G6PD deficient human
erythrocytes. Jagrati Jain, Narayan D Chaurasiya, NP Dhammika Nanayakkara, James
D McChesney, Larry A Walker and Babu L Tekwani. 16th Annual Oxford International
Conference on the Science of Botanicals (ICSB) Meeting. April 11 th - 14th, 2016.
6. NRH: Quinone Reductase 2 (NQO2) Protects Against Hemolytic Toxicity Induced by
Primaquine Antimalarial in G6PD Deficient Human Erythrocytes. Jagrati Jain,
Narayan D Chaurasiya, NP Dhammika Nanayakkara, James D McChesney, Larry A
Walker and Babu L Tekwani. Abstract Number 970. 64th Annual Meeting, American
Society of Tropical Medicine & Hygiene (ASTMH), 2015. October 25 th – 29th, 2015.
7. Protective role of NRH: Quinone Reductase 2 (NQO2) in Primaquine-induced
hemolytic toxicity. Jagrati Jain, Narayan D Chaurasiya, NP Dhammika Nanayakkara,
James D McChesney, Larry A Walker and Babu L Tekwani. Drug Discovery and
Development Colloquium (DDDC). June 22nd-24th, 2015.
8. Investigating the mechanism of Primaquine-induced hemolytic toxicity with natural
product inhibitors of NRH: Quinone Reductase 2 (NQO2). Jagrati Jain, Narayan D
Chaurasiya, NP Dhammika Nanayakkara, James D McChesney, Larry A Walker and Babu
L Tekwani. 42nd Annual Meeting, Medicinal Chemistry-Pharmacognosy MeetingMiniature (MALTO). May 17th-19th, 2014.
9. Inhibitors of Ubiquitin E3 ligase arrest the growth of Plasmodium falciparum at
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trophozoite stage. Jagrati Jain, Larry A. Walker, Babu L. Tekwani. 3rd Malaria
Symposium. April 22nd, 2015.
10. Effect of Quinone Reductase 2 (NQO2) Inhibitor on Primaquine-Induced Hemolytic
Toxicity. Jagrati Jain, Narayan D Chaurasiya, NP Dhammika Nanayakkara, James D
McChesney, Larry A Walker and Babu L Tekwani. 3rd Malaria Symposium. April 22nd,
2015.
11. Effect of Quinone Reductase 2 (NQO2) Inhibitor Melatonin on Primaquine-Induced
Hemolysis. Jagrati Jain, Narayan D Chaurasiya, NP Dhammika Nanayakkara, Larry A
Walker and Babu L Tekwani. 15th Annual Oxford International Conference on the Science
of Botanicals (ICSB). April 13th - 16th, 2015.
12. Inhibitors of ubiquitin E3 ligase as potential new antimalarial drug leads. Jagrati Jain,
Rajnish Sahu, Larry A. Walker, Babu L. Tekwani. Abstract Number 295. 63 rd Annual
Meeting, American Society of Tropical Medicine & Hygiene (ASTMH). November 3 rd,
2014.
13. Inhibitors of ubiquitin e3 ligase as potential new antimalarial drug leads. Jagrati
Jain, Rajnish Sahu, Larry A. Walker, Babu L. Tekwani. 41st Annual Meeting, Medicinal
Chemistry-Pharmacognosy Meeting-Miniature (MALTO). May 18th-20th, 2014.
Podium Presentations:
1. Biochemical and molecular assessment of toxicity of Primaquine (PQ) metabolites
on human erythrocytes. Prospectus defense. February 7th, 2017. School of Pharmacy,
University of Mississippi.
2. Unraveling pathways for hemolytic toxicity of nitrofurantoin in human
erythrocytes. Original research proposal (ORP) defense. May 4th, 2016. School of
Pharmacy, University of Mississippi
3. Targeting ubiquitin-dependent protein degradation pathway of Plasmodium
falciparum: Evaluation of the antimalarial activity of the inhibitors of ubiquitin E3
ligase. Jagrati Jain, Rajnish Sahu, Larry A. Walker, Babu L. Tekwani. 2nd Malaria
Symposium. April 24th, 2014.
Conferences Attended:
1. American Society of Tropical Medicine & Hygiene (ASTMH), 65th Annual
Meeting, November 13th-17th, 2016 at Atlanta Marriott Marquis and Hilton Atlanta,
Atlanta, Georgia USA.
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2. 4th Malaria Symposium. April 25th, 2016. E. F. Yerby Conference Center, Grove
Loop, University, MS USA.
3. Oxford International Conference on the Science of Botanicals (ICSB) 16th
Annual Meeting. April 11th - 14th, 2016. Oxford Conference Center, Oxford, MS
USA.
4. American Society of Tropical Medicine & Hygiene (ASTMH), 64th Annual
Meeting, October 25th – 29th, 2015 at Philadelphia Marriott Downtown, Philadelphia,
Pennsylvania, USA.
5. Drug Discovery and Development Colloquium (DDDC), June 22nd-24th, 2015. Thad
Cochran Research Center, University, Mississippi, USA.
6. Medicinal Chemistry-Pharmacognosy Meeting-Miniature (MALTO) 42nd Annual
Meeting, May 17th-19th, 2014 – University of Mississippi, University, Mississippi,
USA.
7. 3rd Malaria Symposium. April 22nd, 2015. E. F. Yerby Conference Center, Grove
Loop, University, Mississippi, USA.
8. Oxford International Conference on the Science of Botanicals (ICSB) 15th Annual
Meeting. April 13th - 16th, 2015. Oxford Conference Center, Oxford, Mississippi, USA.
9. Southern Central Chapter of the Society of Toxicology Meeting, 2014 Fall
Annual Meeting. October 23th-24th, 2014. University of Mississippi, University,
Mississippi, USA.
10. American Society of Tropical Medicine & Hygiene (ASTMH), 63rd Annual
Meeting, November 2th-6th, 2014, Sheraton New Orleans and the New Orleans
Marriott, New Orleans, Louisiana, USA.
11. The American Society of Pharmacognosy (ASP), 55th Annual Meeting, August 2nd6th, 2014, Oxford Conference Center, Oxford, Mississippi, USA.
12. Medicinal Chemistry-Pharmacognosy Meeting-Miniature (MALTO) 41st
Annual Meeting, May 18th-20th, 2014. The University of Tennessee Health Science
Center, Memphis, Tennessee, USA.
13. 2nd Malaria Symposium. April 24th, 2014. E. F. Yerby Conference Center, Grove
Loop, University, Mississippi, USA.
14. 1st Malaria Symposium. April 2013. E. F. Yerby Conference Center, Grove Loop,
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University, Mississippi, USA.

Technical/Scientific Workshops Attended:
1. Metabolomics Workshop. June 14th- 18th, 2015. University of Alabama, Birmingham,
Tennessee, USA.
2. EuPathDB Workshop. June 17th- 20th, 2012. University of Georgia, Athens, Georgia,
USA.
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